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Pituitary adenylate cyclase-activating polypeptide (PACAP)-mediated activation of its 
G protein-coupled receptor PAC1 results in activation of the two G proteins Gs and 
Gq to alter second messenger generation and gene transcription in the nervous system, 
important for homeostatic responses to stress and injury. PAC1 occurs in different 
splice variants of the third intracellular loop, designated PAC1null, hop or hip, 
affecting second messenger generation as shown in non-neural cells. At the 
splanchnico-adrenomedullary synapse, PACAP is required for prolonged 
catecholamine secretion from chromaffin cells to restore homeostasis during 
prolonged periods of stress. In the central nervous system, PACAP is neuroprotective 
in neurodegenerative conditions associated with e.g., stroke. 
In the present study, PAC1 splice variant-specific second messenger 
production and activation of homeostatic responses were investigated in neuro-
endocrine and neural cells. Heterologous expression of the major PAC1 splice variant 
of adrenomedullary chromaffin cells, PAC1hop, in pheochromocytoma PC12-G cells 
reconstituted a PACAP-mediated Ca
2+
 and prolonged secretory response similar to the 
one observed in primary chromaffin cells. The Ca
2+
 response mediated by PAC1null 
was somewhat smaller and PAC1hip failed to couple to Ca
2+
. Neither variant 
conferred prolonged catecholamine release, suggesting that expression of the hop 
cassette in the third intracellular loop of the receptor is required for sustained 
catecholamine release from neuroendocrine cells. 
In neuroblastoma x glioma NG108-15 cells, heterologous expression of the 
PAC1hop, null and hip receptor conferred PACAP-mediated intracellular cAMP 
generation, while elevation of [Ca
2+
]i occurred efficiently in PAC1hop- and to a lesser 
extent in PAC1null-expressing cells. Expression of PAC1hip did not confer an 
intracellular Ca
2+
 response, indicating that PAC1hop is the receptor variant most 
efficiently coupled to combinatorial signaling through cAMP and Ca
2+
. PAC1hop-
mediated signaling activated the mitogen-activated protein kinases (MAPK) 
extracellular signal-regulated kinases 1 and 2 (ERK1/2). Signaling to ERK proceeded 
through cAMP independently of the cAMP dependent protein kinase (PKA). PACAP 
induced transcription of the gene encoding the putative neuroprotectant stanniocalcin 
1 (STC1), which has previously been implicated in neuronal resistance to hypoxic/ 
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ischemic insult; gene induction proceeded through ERK but not PKA. Cyclic AMP 
generation by forskolin did not activate ERK in NG108-15 cells, but rather induced 
STC1 mRNA elevation through the canonical PKA dependent pathway. This suggests 
that activation of non-canonical cAMP signaling, mediating ERK-dependent gene 
induction, requires additional signaling through Ca
2+
 via PAC1hop in these cells. 
Primary rat cortical neurons expressed predominantly the PAC1hop and null 
variants. Exposure of cortical neurons to PACAP resulted in elevation of the two 
second messengers cAMP and Ca
2+
, activation of ERK1/2, and induction of STC1 
gene transcription. PACAP-mediated ERK activation proceeded through cAMP but 
not PKA, and STC1 was induced via ERK but not PKA. Pharmacological stimulation 
of adenylate cyclases by forskolin also resulted in increased ERK phosphorylation 
and STC1 mRNA elevation independently of PKA. These results indicate that cAMP 
production alone is sufficient to activate ERK in differentiated cortical neurons, 
unlike in the less differentiated NG108-15 cell line. Induction of another PACAP 
target gene, brain-derived neurotrophic factor (BDNF), occurred through the 
canonical cAMP/PKA pathway. 
PACAP has been shown by our laboratory and others to be neuroprotective 
against ischemia in rodent stroke models. To begin to define the mechanism of this 
neuroprotection, we employed two cell culture stroke models. Rat cortical neurons 
subjected to either oxygen-glucose-deprivation or glutamate-induced excitotoxicity 
underwent cell death as expected. However, treatment with PACAP did not increase 
neuronal survival in either of the two models, and STC1 over-expression also failed to 
increase resistance to neuronal cell death during glutamate-induced excitotoxicity. 
These data suggest that the protective effects of the neurotrophic peptide PACAP and 
the putative neuroprotectant STC1 during neurodegenerative conditions in vivo are 
mediated through cells absent in cultures of cortical neurons, such as glial cells. 
In conclusion, the present study has demonstrated that expression of different 
PAC1 splice variants determines the degree of activation of two different second 
messenger pathways that may mediate different functional outcomes during stress-
responding. PACAP mediates ERK activation and STC1 induction via non-canonical 
cAMP signaling. The selective pharmacological activation of this potentially 
neuroprotective pathway, which is different from the cAMP/PKA pathway critical for 
learning and memory, could have therapeutic implications for neuroprotection in vivo. 




Aktivierung des G-Protein-gekoppelten Rezeptors PAC1 durch PACAP (pituitary 
adenylate cyclase-activating polypeptide) resultiert in Aktivierung der beiden G-
Proteine Gs und Gq und führt über die Produktion von Second Messengern 
(sekundären Botenstoffen) zur Aktivierung von Gentranskription, die essentiell für die 
homöostatische Stressantwort zu sein scheint. Durch differenzielles Splicing der 
dritten intrazellulären Schleife von PAC1 entstehen sogenannte PAC1null-, hop- und 
hip-Rezeptoren. In non-neuralen Zellen konnte gezeigt werden, dass die Expression 
verschiedener Rezeptor-Varianten die Generation von Second Messengern 
beeinflusst. Als Kotransmitter an der splanchnico-adrenomedullären Synapse ist 
PACAP für anhaltende Katecholamin-Freisetzung von chromaffinen Zellen 
unentbehrlich, welche zur Wiederherstellung der Homöostase während anhaltendem 
Stress dient. Im zentralen Nervensystem ist PACAP neuroprotektiv in Assoziation mit 
neurodegenerativen Erkrankungen wie z.B. Schlaganfall.  
 In der vorliegenden Arbeit wurde die Produktion von Second Messengern 
durch verschiedene PAC1-Splice-Varianten und die Aktivierung homöostatischer 
Antworten in neuroendokrinen und neuralen Zellen untersucht. Heterologe 
Expression von PAC1hop, der Haupt-Variante adrenomedullärer chromaffiner Zellen, 
in Phäochromozytom PC12-G Zellen, resultierte in einer PACAP-evozierten Ca
2+
- 
und anhaltenden sekretorischen Antwort, ähnlich der in primären chromaffinen 
Zellen. Auch die Aktivierung von PAC1null, jedoch nicht von PAC1hip, vermittelte 
eine intrazelluläre Ca
2+
-Antwort; diese war etwas geringer als die durch PAC1hop 
vermittelte. Weder PAC1null- noch PAC1hip-Aktivierung resultierte in anhaltender 
Katecholamin-Freisetzung. Dies zeigt die Notwendigkeit der Expression der hop-
Kassette in der dritten intrazellulären Schleife des PAC1-Rezeptors für anhaltende 
Freisetzung von Katecholaminen aus neuroendokrinen Zellen. 
 Heterologe Expression von PAC1hop-, null- und hip-Rezeptoren in NG108-15 
Zellen (ein Neuroblastom-Gliom Hybrid) resultierte in PACAP-aktivierter Produktion 
von zyklischem AMP (cAMP), während eine intrazelluläre Ca
2+
-Antwort nur durch 
PAC1hop und etwas geringer durch PAC1null vermittelt wurde. Diese Ergebnisse 
deuten darauf hin, dass eine Signalkopplung an Ca
2+
 durch Expression der hop-
Kassette erhöht und durch Expression der hip-Kassette aufgehoben wird; eine 
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effiziente duale Signaltransduktion durch cAMP und Ca
2+
 wird also nur durch die 
hop-Variante des PAC1-Rezeptors vermittelt. Diese resultierte in einer Aktivierung 
der MAP Kinasen (mitogen-activated protein kinases) ERK1/2 (extracellular signal-
regulated kinases 1 and 2). Zyklisches AMP, jedoch nicht die cAMP-abhängige 
Proteinkinase (PKA) waren in die Aktivierung von ERK involviert. PACAP 
induzierte das putativ neuroprotektive Gen Stanniocalcin 1 (STC1), welches laut 
Literaturstand neuronale Resistenz bei hypoxischem/ischämischem Insult vermittelt; 
die Genaktivierung erfolgte via ERK, unabhängig von PKA. Direkte Stimulation von 
Adenylatzyklasen durch Forskolin hingegen löste keine ERK-Aktivierung aus und 
STC1-Induktion wurde durch kanonische (PKA-abhängige) Signaltransduktion 
vermittelt. In NG108-15 Zellen scheinen also zur Aktivierung von nicht-kanonischer 
cAMP-abhängiger Signaltransduktion, welche ERK-abhängige Geninduktion 
vermittelt, zusätzlich PAC1hop-aktivierte Ca
2+
-Signalwege nötig zu sein. 
Primäre kortikale Neuronen exprimierten hauptsächlich die PAC1hop- und 
PAC1null-Varianten. PACAP-Behandlung resultierte in einer intrazellulären 
Erhöhung von cAMP und Ca
2+
, ERK-Aktivierung und STC1-Induktion. Die 
Aktivierung von ERK war cAMP-abhängig und PKA-unabhängig. STC1-Induktion 
wurde durch ERK und nicht durch PKA vermittelt. Forskolin-Behandlung resultierte 
ebenso in PKA-unabhängiger ERK-Aktivierung sowie STC1-Induktion. Dies zeigt, 
dass in differenzierten kortikalen Neuronen, im Gegensatz zu weniger differenzierten 
NG108-15 Zellen, gesteigerte cAMP-Produktion zur ERK-Aktivierung ausreicht. 
PACAP-vermittelte Induktion von brain-derived neurotrophic factor (BDNF) mRNA 
hingegen war PKA-abhängig. 
 Im Tiermodell konnte gezeigt werden, dass PACAP im Zusammenhang mit 
Schlaganfall neuroprotektiv ist. Um erste Einsichten in den Mechanismus dieser 
Neuroprotektion zu bekommen, wurden zwei Zellkultur-Modelle für Schlaganfall 
angewandt. Sauerstoff-Glukose-Deprivation und Glutamat-induzierte Excitotoxizität 
lösten, wie erwartet, in kortikaler Neuronenkultur Zelltod aus, der sich jedoch als 
PACAP-resistent herausstellte. Auch durch STC1-Überexpression konnte der durch 
Excitotoxizität ausgelöste Zelltod nicht reduziert werden. Diese Ergebnisse deuten 
darauf hin, dass die neuroprotektiven Effekte von PACAP und STC1 während 
neurodegenerativen Erkrankungen durch Zellen vermittelt werden, die in kortikaler 
Neuronenkultur fehlten, wie z.B. Gliazellen. 
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Insgesamt weisen die Befunde dieser Arbeit darauf hin, dass die Expression 
verschiedener PAC1-Varianten den Aktivierungsgrad zweier Second Messengers 
bedingt und damit den funktionellen Ausgang nach Stress-Einwirkung bestimmt. 
PACAP-vermittelte ERK-Aktivierung und STC1-Induktion via nicht kanonischer 
cAMP-abhängiger Signaltransduktion unterscheidet sich von der kanonischen PKA-
vermittelten Signaltransduktion, welche in physiologischen Prozessen wie 
Gedächtniskonsolidierung von Bedeutung ist. Die selektive pharmakologische 
Aktivierung dieses potenziell neuroprotektiven nicht-kanonischen Signalweges hat 
therapeutische Implikation für Neuroprotektion in vivo. 




AC adenylate cyclase 
ACh acetylcholine 
AM ester acetoxymethyl ester 
ANOVA analysis of variance 
ATP adenosine triphosphate 
BAPTA bis(2-aminophenoxy)ethane tetraacetic acid 
BBB blood-brain barrier 
BCC bovine chromaffin cell 
BDNF brain-derived neurotrophic factor 
bp base pair 





]i intracellular calcium concentration 
cAMP cyclic adenosine 3ʹ5ʹ-monophosphate 
cDNA complementary DNA 
CMV cytomegalovirus 
CNS central nervous system 
CREB cAMP response element binding protein 
Da dalton 
DCV dense-core vesicle 
ddAd 2′5′-dideoxyadenosine 
DEPC diethylpyrocarbonate 
div days in vitro 
DMEM Dulbecco‟s modified Eagle‟s medium 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxynucleoside triphosphate 
DTT dithiothreitol 
EC50 half maximal effective concentration 
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EDTA ethylenediaminetetraacetic acid 
EGF epidermal growth factor 
eGFP enhanced green fluorescent protein 
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Epac exchange protein directly activated by cAMP 
Epi epinephrine 
ER endoplasmic reticulum 
ERK extracellular signal-regulated kinase 
et al. et alteres 
EtBr ethidium bromide 
F forward 
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FCS fetal calf serum 
G protein guanine nucleotide-binding protein 
G guanidine 
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GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GDP guanosine diphosphate 
GEF guanine nucleotide exchange factor 
GFP green fluorescent protein 
GHRH growth hormone releasing hormone 
GPCR G protein-coupled receptor 
GRK GPCR kinase 
GTP guanosine triphosphate 
GTPase guanosine triphosphatase 
HAT hypoxanthine, aminopterine, thymidine 
HEK human embryonic kidney 
HEPES hydroxyethylpiperazine ethane sulfonic acid 
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MAPK mitogen-activated protein kinase 
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MEK MAPK/ERK kinase 
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mRNA messenger RNA 
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PIP2 or PtdIns(4,5)P2 phosphatidylinositol 4,5-bisphosphate 
PKA protein kinase A 
PKC protein kinase C 
PLC phospholipase C 
PLD phospholipase D 
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pMCAO permanent MCAO 
PNS peripheral nervous system 
Pol polymerase 
PRP PACAP-related peptide 
R reverse 
Rev regulator of virion 
RNA ribonucleic acid 
RPM revolutions per minute 
RRP readily releasable pool 
RT reverse transcriptase 
RT room temperature 
RTK receptor tyrosine kinase 
SAPK2/p38 stress-activated protein kinase 2 
SDS sodium dodecyl sulfate 
SEM standard error of the mean 
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SOCC store-operated calcium channel 
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SSV small synaptic vesicle 
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TAE tris acetate EDTA 
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TH tyrosine hydroxylase 
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VAChT vesicular acetylcholine transporter 
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1.1 Classical ‘fast’ versus neuropeptide ‘slow’ transmitters 
Neuropeptides are widely distributed in the nervous system, where they have 
important functions as signaling molecules. They generally co-exist with classical 
neurotransmitters in the same neuron. Classical „fast‟ neurotransmitters such as 
glutamate or acetylcholine (ACh) are released from small synaptic vesicles (SSVs), 
generating electrical signals by regulating membrane ion flux through ionotropic 
receptors or ligand-gated ion channels. Neuropeptide „slow‟ transmitters such as 
pituitary adenylate cyclase-activating polypeptide (PACAP), in contrast, are released 
from large dense-core vesicles (LDCVs), bind to metabotropic G protein-coupled 
receptors (GPCRs)
a
 and alter the generation of intracellular second messengers such 
as cyclic adenosine 3ʹ5ʹ-monophosphate (cAMP) and calcium involved in modulatory 
processes over longer time periods. Low-frequency activity leads to the release of 
classical neurotransmitters, whereas high-frequency stimulation is needed to trigger 
the release of neuropeptides, which is of particular importance when the nervous 
system is challenged (Hokfelt et al., 2003; Hokfelt et al., 2000). 
1.2 Slow transmitters activate G protein-coupled receptors (GPCRs) 
G protein-coupled receptors (GPCRs) are the largest family of membrane proteins in 
vertebrates, comprising 3-5% of all gene-encoded proteins. They mediate the majority 
of physiological responses to neurotransmitters and hormones and to sensory stimuli 
such as photons and odorants. About half of the therapeutic drugs prescribed 
worldwide modulate the activity of GPCRs. GPCRs share a common molecular 
architecture of a seven-transmembrane configuration (hence the alternate name of 
seven-transmembrane receptors) and a common signaling mechanism through 
coupling to heterotrimeric G proteins and regulation of second messenger-generating 
enzymes (Gudermann et al., 1997). 
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 The GPCR superfamily consists of approximately 1,000 members. 
Mammalian GPCRs are divided into three main families (A, B and C) based on 
sequence and structural similarities. All members have seven membrane-spanning 
domains separated by alternating intracellular (ic1, ic2, ic3) and extracellular loops 
(ec1, ec2, ec3), and an extracellular amino-terminal and intracellular carboxy-terminal 
domain. Family A is the largest and most diverse group and includes the light-sensing 
rhodopsin, adrenergic receptors, the olfactory subgroup, chemokine receptors and the 
majority of peptide GPCRs, including galanin, neuropeptide Y (NPY), oxytocin, 
vasopressin, melanocortin and opioid receptors (Lee et al., 2002). The first crystal 
structure of a seven-transmembrane (7TM) receptor solved was that for rhodopsin 
(Palczewski et al., 2000), followed by those for adrenergic receptors (Cherezov et al., 
2007; Warne et al., 2008). Family B consists of a small group of receptors (15 in all) 
with large N-termini, which are activated by the peptides secretin, glucagon, 
vasoactive intestinal polypeptide (VIP), PACAP, growth hormone releasing hormone 
(GHRH), glucagon, the glucagon-like peptides (GLP-1 and GLP-2), gastric inhibitory 
peptide (GIP), corticotropin-releasing hormone (CRH), urocortin, parathyroid 
hormone (PTH), tuberoinfundibular peptide of 39 residues (TIP39), calcitonin, 
calcitonin gene related peptide (CGRP) and adrenomedullin (Martin et al., 2005). The 
first cloned receptor of this class was the secretin receptor (Ishihara et al., 1991), 
which had the predicted 7TM topology but only little sequence homology with family 
A GPCRs and therefore became the archetypical member of the second GPCR class. 
Family C is the smallest group and includes receptors for metabotropic glutamate and 
GABA-B receptors functioning as dimers (Pierce et al., 2002). 
1.2.1 GPCR-mediated signaling 
Classical GPCR signaling is initiated by binding of ligands (such as hormones, 
neurotransmitters or sensory stimuli) inducing conformational changes in the receptor 
and increasing the affinity for G protein binding. The activated receptor acts as a 
guanine-nucleotide exchange factor (GEF) for the α-subunit of the heterotrimeric G 
protein catalyzing the exchange of GDP for GTP. The GTP-bound α-subunit and the 
tightly linked βγ-complex dissociate from each other and the receptor and regulate the 
activity of several effector proteins, including enzymes that regulate the generation of 
intracellular second messengers or ion channels. The multi-component signaling 
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system of GPCRs creates the potential for tremendous signal amplification within the 
cell. The intrinsic GTPase activity of the α-subunit returns the G protein to the 
inactive GDP-bound heterotrimeric state and ends the signaling cycle. 
Multiple G protein subtypes exist, which are composed of three different 
subunits (α, β and γ) and are generally referred to by their α-subunit. Gα subunits are 
divided into four families, regulating the activity of different effectors that in turn 
generate different second messengers. Proteins of the Gαs family activate and proteins 
of the Gαi family inhibit a group of effector enzymes called adenylate cyclases (ACs) 
that catalyze the conversion of adenosine triphosphate (ATP) to the second messenger 
cAMP. Cyclic AMP activates the cAMP-dependent protein kinase (PKA), the 
canonical cAMP effector (Kuo and Greengard, 1969), and other so called non-
canonical downstream effectors such as cyclic nucleotide-gated ion channels (Biel 
and Michalakis, 2009) and exchange proteins directly activated by cAMP (Epac1 and 
2), also known as cAMP-GEFs, which regulate guanine nucleotide exchange of the 
small G protein Rap (de Rooij et al., 1998; Kawasaki et al., 1998). Nine different ACs 
with a common 12 membrane-spanning domain structure are known. All 
transmembrane ACs (tmACs) are activated by Gαs. AC I, III and VIII are in addition 
activated by calcium, whereas AC V and VI are inhibited by calcium. Another source 
for cAMP generation is the soluble AC (sAC), which is activated by calcium and 
bicarbonate (Hanoune and Defer, 2001). The Gαq family regulates the activity of four 
isoforms of phospholipase Cβ (PLCβ). PLCβ isoenzymes hydrolyze the membrane 
lipid phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2 or PIP2) into diacyl 
glycerol (DAG) and inositol-1,4,5-trisphosphate (Ins(1,4,5)P3 or IP3). IP3 regulates the 
release of calcium from intracellular stores such as the endoplasmic reticulum (ER) 
through activation of IP3 receptors. Membrane-bound DAG controls together with 
calcium the activity of several isoforms of protein kinase C (PKC). PKC and PKA are 
serine/threonine kinases phosphorylating hydroxyl groups of the amino acids serine 
and threonine in respective target proteins. The Gα12 family regulates the activity of 
RhoGEFs. Rho is a small, monomeric GTPase of the Ras superfamily, which together 
with other members of the Ras superfamily (Ras, Rab, Arf and Ran) regulates cellular 
processes such as proliferation, differentiation, apoptosis and cytoskeleton 
organization (Etienne-Manneville and Hall, 2002). Among targets of the βγ-
heterodimer are ion channels, PLCβ isoenzymes, phospholipase A2 (PLA2) and 
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GPCR kinases (GRKs) (Fig. 1). To date 16 α, five β and 12 γ proteins have been 
cloned, the combination of which can give rise to more than 800 heterotrimeric G 
proteins. In addition to signaling through the α-subunit and the βγ-dimer, recent 
research indicates that alternate signaling mechanisms are available to GPCRs 
including the activation of extracellular signal-regulated kinase (ERK) and other 
downstream kinases via formation and internalization of signaling complexes within 
the cell  (Luttrell, 2006; Neer, 1995; Ritter and Hall, 2009). 
 
 
Figure 1: Classical GPCR-mediated signaling. An extracellular agonist binds to and 
activates the receptor. Activated G proteins regulate effector proteins such as enzymes (e.g., 
adenylate cyclases and PLCβ) and ion channels. Activated enzymes modulate downstream 
effectors directly or generate second messengers such as cAMP that further regulate certain 
downstream effectors (from Ritter and Hall, 2009). 
1.2.2 Termination of G protein-mediated signaling 
GPCR-mediated signaling is regulated at multiple levels, from second messengers to 
the receptor itself. The second messenger cAMP for example is degraded 
enzymatically by cAMP phosphodiesterases (PDEs). The intrinsic GTPase activity of 
the α-subunit of the G-protein is accelerated by GTPase-activating proteins (GAPs), 
that can be part of the effector itself or members of the family of RGS (regulators of 
G protein signaling) proteins, deactivating G proteins by allowing heterotrimers to 
reform. 
Receptor function itself is negatively regulated through desensitization, a 
phenomenon where receptor signaling is rapidly dampened even in the continuous 
presence of the ligand. Second messenger-dependent protein kinases like PKA and 
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PKC can phosphorylate serine and threonine residues within cytoplasmic loops and 
the C-terminal tail of the receptor and directly impair G protein coupling. PKA- and 
PKC-mediated phosphorylation can also cause heterologous desensitization, in which 
kinase activation by one receptor leads to phosphorylation of another. GPCR kinases 
(GRKs) phosphorylate serine and threonine residues within the C-terminal tail and the 
third intracellular loop of the agonist-bound receptor (homologous desensitization) 
increasing the affinity for arrestin binding, which sterically inhibits further G protein 
binding. Moreover, β-arrestin 1 and 2 (which are the two ubiquitously expressed 
arrestins in contrast to the two visual arrestins in the retina) interact with clathrin and 
the clathrin adaptor AP2 to drive GPCR internalization into endosomes. Interestingly, 
β-arrestins not only regulate GPCR desensitization but also initiate distinct signaling 
pathways, including activation of the mitogen-activated protein kinase (MAPK) 
extracellular signal-regulated kinase (ERK) pathway. Following internalization, 
receptors can be trafficked to lysosomes, where they are degraded, or to recycling 
endosomes, where they are dephosphorylated and returned to the plasma membrane in 
their basal state. Finally, the expression of cell surface receptors is regulated at the 
transcriptional and translational level (Luttrell, 2006; Pierce et al., 2002). 
1.3 Pituitary adenylate cyclase-activating polypeptide (PACAP) 
1.3.1 PACAP, a neuropeptide slow transmitter 
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a peptide that was 
isolated from ovine hypothalamus based on its ability to stimulate cAMP in rat 
anterior pituitary cells (Miyata et al., 1989). The mature peptide PACAP occurs in 
two C-terminally α-amidated forms, PACAP-27 and PACAP-38, with PACAP-27 
being identical to the first 27 amino acids of PACAP-38. PACAP-27 has 68% 
sequence homology with vasoactive intestinal polypeptide (VIP) (Said and Mutt, 
1970), identifying PACAP as a member of the VIP-secretin-GHRH-glucagon 
superfamily (Miyata et al., 1990) (Fig. 2). The first 27 amino acids of PACAP have 
almost been completely preserved through vertebrate evolution, from fish to 
mammals, and are responsible for its biological activity. Mature PACAP is generated 
through cleavage of the 176-amino acid prepro-protein by various prohormone 
convertases (PCs). Another 29-amino acid peptide, PACAP-related peptide (PRP), is 
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generated from prepro-PACAP, and exhibits only moderate homology with PACAP. 
The structure of the PACAP precursor is similar to that of the VIP precursor, which 
generates the 28-amino acid peptide VIP and the 27-amino acid VIP-related peptide 
histidine methionine (PHM) in humans or peptide histidine isoleucine (PHI) in 
rodents, sheep and chicken (Arimura, 1998; Mustafa and Eiden, 2006; Sherwood et 
al., 2000; Vaudry et al., 2009). 
PACAP‟s central and C-terminal domain bind to the N-terminal domain of the 
receptor and the N-terminal domain of the peptide interacts with the juxtamembrane 
domains of the receptor, stimulating intracellular signaling. The N-terminally 
truncated form of PACAP, PACAP(6-38), is a potent receptor antagonist (Robberecht 
et al., 1992). Maxadilan, a naturally occurring vasodilator polypeptide of 61 amino 
acids, is a potent and selective PAC1 receptor agonist and was isolated from the 
salivary gland of the sand fly. Interestingly, maxadilan possesses no significant 




VIP  ...AV...N.T.L..........NSI.N-NH2 
Figure 2: Amino acid sequences of human PACAP and VIP (., amino acid identical with 
PACAP-38). 
PACAP is widely expressed in the nervous system, e.g., the hypothalamus, 
cerebral cortex, amygdala, nucleus accumbens, hippocampus and cerebellum of the 
central nervous system, and in sensory neurons, sympathetic preganglionic neurons 
and parasympathetic pre- and postganglionic neurons of the peripheral nervous 
system. PACAP-38 is the predominant form expressed (Arimura et al., 1991; Ghatei 
et al., 1993; Hamelink et al., 2002b; Hannibal, 2002; Sundler et al., 1996). Moreover, 
PACAP is found in tumors, particularly in gliomas, neuroblastomas, 
pheochromocytomas, pancreatic carcinomas and pituitary tumors, where the 
stimulation of cAMP can lead to cell proliferation and tumorigenesis (Fahrenkrug et 
al., 1995; Takahashi et al., 1993a; Takahashi et al., 1993b). PACAP is present in the 
embryonic brain, where its concentration increases with prenatal maturation (Masuo 
et al., 1994). 
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1.3.2 PACAP receptors, members of the GPCR family B 
As neuropeptides, PACAP and VIP bind to G protein-coupled receptors (GPCRs). 
The high sequence homology between these two peptides suggests that they can bind 
to common GPCRs. Three VIP/PACAP receptors have been identified named 
VPAC1, VPAC2 and PAC1, which are members of the family B of the GPCR 
superfamily  (Harmar, 2001; Harmar et al., 1998; Ishihara et al., 1992; Lutz et al., 
1993; Pisegna and Wank, 1993). VPAC1 and 2 bind VIP and PACAP with similar 
affinities (type II binding sites) whereas PAC1 binds PACAP with high affinity and 
VIP with much lower affinity (type I binding sites; Fig. 3). 
 
Figure 3: VIP and PACAP bind to three common GPCRs. VPAC1 and VPAC2 bind VIP 
and PACAP with similar affinities (type II binding sites), whereas PAC1 is a PACAP-preferring 
receptor (type I binding sites). 
Several isoforms of the PAC1 receptor have been identified in vivo. These are 
mainly generated through alternative splicing within two regions of the PAC1 gene: 
the N-terminus and the third intracellular loop (ic3). N-terminal variants result from 
deletions (21 or 57 amino acids) at the N-terminal extracellular domain affecting 
ligand binding and the relative potencies of the ligands in second messenger 
stimulation (Dautzenberg et al., 1999; Pantaloni et al., 1996). In the rat testis a 24-
amino acid N-terminal insertion (designated 3a) has been identified (Daniel et al., 
2001). Ic3 variants result from the presence or absence of different insertions at the C-
terminal end of the loop, a domain thought to be crucial for interaction with G 
proteins. Each insertion, designated hip and hop, consists of an 84-bp cassette. The 
alternative use of two contiguous consensus splice acceptor sites at the 5`-end of the 
hop cassette generates hop1 and hop2. The hip cassette can be included together with 
the hop cassette to give rise to hiphop. The null form does not contain any insert. The 
hop cassette encodes a consensus motif for phosphorylation by PKC (Spengler et al., 
1993) (Fig. 4). 




Figure 4: Amino acid sequences of the third intracellular loop of rat PAC1. Alternative 
splicing gives rise to hop1, hop2, hip, null, hiphop1 and hiphop2 (not shown; PKC 
phosphorylation site is underlined; arrowheads indicate the splice sites for the generation of 
the 21 and 57 amino acid N-terminal deletions (designated short and very short N-terminus, 
respectively); Y marks N-glycosylation sites; TM5 and 6: transmembrane domain 5 and 6; 
modified from Spengler et al., 1993). 
Type I and II binding sites and their corresponding receptor transcripts are 
located throughout the central and peripheral nervous system. Both types of binding 
sites are found in early embryonic stages throughout the nervous system and their 
density increases during embryonic and early postnatal development. Type I sites are 
generally more abundant than type II sites. Brain structures with high concentrations 
of type I binding sites and PAC1 receptor expression include the cerebral and 
cerebellar cortex, hypothalamus, thalamus, hippocampus, olfactory bulb, amygdala, 
substantia nigra and brain stem. Type II binding sites show complementary 
distribution; VPAC1 is predominantly expressed in the cerebral cortex and 
hippocampus and strong VPAC2 expression is found in thalamus, hypothalamus and 
amygdala (Hashimoto et al., 1993; Joo et al., 2004; Sheward et al., 1995; Shioda et 
al., 1997). The predominant forms of the PAC1 receptor in the brain are the ic3-splice 
variants containing the hop cassette (PAC1hop) and without any cassette (PAC1null). 
The embryonic brain expresses high levels of receptors containing a short N-terminus 
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lacking 21 amino acids, whereas the receptor with a full-length N-terminus is the 
predominant form in the adult brain. Interestingly, the short N-terminus shows higher 
sequence homology with other members of the class B GPCR subfamily and increases 
the potency of VIP at the receptor (Cavallaro et al., 1996; Dautzenberg et al., 1999; 
Harmar, 2001; Lutz et al., 2006; Pantaloni et al., 1996; Pisegna and Wank, 1996; 
Zhou et al., 2000). Receptors are not only present on neurons but are also expressed in 
glial cells (Grimaldi and Cavallaro, 1999; Pilzer and Gozes, 2006; Tatsuno et al., 
1991). Moreover, PACAP receptors are expressed in the anterior and posterior lobe of 
the pituitary gland, the adrenal medulla (Hashimoto et al., 1996; Mazzocchi et al., 
2002; Moller and Sundler, 1996; Shioda et al., 2000) and many other tissues and 
organs including the retina, placenta and testis as well as cells of the digestive, 
respiratory, cardiovascular and immune system. The PAC1hop1 receptor with a full-
length N-terminus is the predominant variant expressed in chromaffin cells of the 
adrenal medulla (Mustafa et al., 2007; Nogi et al., 1997; Ushiyama et al., 2007). 
PACAP receptors are also widely expressed in tumor cells from e.g., 
pheochromocytomas and neuroblastomas (Waschek et al., 1995; Watanabe et al., 
1990). The very widespread distribution of PACAP and its receptors as well as their 
expression during ontogenesis is highly supportive of the fact that PACAP-mediated 
signaling is involved in the regulation of a plethora of biological functions (Mustafa 
and Eiden, 2006; Vaudry et al., 2009; Vaudry et al., 2000b). 
1.3.3 PACAP-mediated signaling 
All PACAP receptors regulate cAMP generation by coupling to adenylate cyclases 
(ACs) through Gαs (Pisegna and Wank, 1993; Spengler et al., 1993; Usdin et al., 
1994). Moreover, stimulation of other second messengers, including phospholipase C 
(PLC), calcium and phospholipase D (PLD) have been reported (Delporte et al., 1995; 
Dickson et al., 2006; MacKenzie et al., 2001; MacKenzie et al., 1996; McCulloch et 
al., 2001; Ronaldson et al., 2002; Spengler et al., 1993; Ulrich et al., 1998). 
Specifically, coupling to PLCβ varies among the different PAC1 receptors 
alternatively spliced in the third intracellular loop. Inositol phosphate (IP) production 
by coupling to PLCβ through Gαq is more efficacious in PAC1hop and null compared 
to hip receptors (Lutz et al., 2006; Pisegna and Wank, 1996; Spengler et al., 1993). 
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The mitogen-activated protein kinases (MAPK) extracellular signal-regulated 
kinase 1 and 2 (ERK1/2) are important mediators in PACAP signaling to the nucleus. 
ERK activity is regulated through a three-component signaling cassette: the 
MAPKKK Raf phosphorylates the MAPKK MEK1/2, which in turn phosphorylates 
the MAPK ERK1/2. Sustained ERK activation by PACAP mediating neuronal 
differentiation requires activation of the Ras-related small G protein Rap1 and 
subsequent stimulation of B-Raf, the neuronal Raf isoform (Barrie et al., 1997; 
Lazarovici et al., 1998; Ravni et al., 2008). 
Differentiation by nerve growth factor (NGF) in PC12 cells is also mediated 
through prolonged ERK activation, whereas proliferation by epidermal growth factor 
(EGF) is mediated through transient ERK activation. The neurotrophic factors NGF 
and EGF activate receptor tyrosine kinases (RTKs) leading to the stimulation of Ras 
and Rap1, inducing the activation of B-Raf (Kao et al., 2001; York et al., 1998). 
Signaling to ERK is determined by the transduction pathway used by the receptor but 
also by the level of receptor expression. The same growth factor receptor can 
stimulate proliferation or differentiation depending on cell context and expression 
level (Greene and Tischler, 1976; Marshall, 1995; Murphy and Blenis, 2006; Santos 
et al., 2007). 
Protein kinase A (PKA) stimulates the activation of B-Raf through Rap1 
leading to neuronal differentiation (Grewal et al., 2000; Vossler et al., 1997), 
however, cAMP-mediated activation of B-Raf can also occur independently of the 
canonical cAMP effector PKA (Dumaz and Marais, 2005). PACAP-mediated 
neuronal differentiation through cAMP, Rap1 and ERK1/2 can also proceed 
independently of PKA (Ravni et al., 2008). 
1.3.4 Pleiotropic biological functions of PACAP 
1.3.4.2 Hypothalamic and behavioral functions 
The high expression of PACAP and its receptors in the hypothalamus indicates that 
PACAP regulates hypothalamic functions. Abundantly expressed in the 
paraventricular and supraoptic nucleus, it stimulates oxytocin and vasopressin release 
in the neural lobe of the pituitary. PACAP also modulates hypothalamic releasing 
hormones that regulate hormone secretion from the anterior pituitary; e.g., PACAP 
can activate corticotropin releasing hormone (CRH) neurons in the paraventricular 
  Introduction 
11 
 
nucleus (PVN), therefore stimulating the release of adrenocorticotropic hormone 
(ACTH) in anterior pituitary cells to increase glucocorticoid levels and enhance stress 
responses (Stroth and Eiden, 2010). In addition to regulating stress responses at the 
level of the hypothalamo-pituitary-adrenal (HPA) axis, PACAP acts as a co-
transmitter at the sympathoadrenal synapse, controlling adrenomedullary 
catecholamine synthesis and secretion during prolonged splanchnic nerve stimulation 
in response to metabolic stress (hypoglycemia). (Hamelink et al., 2002b; Stroth et al., 
2011). PACAP and its receptors are expressed in neurons of the arcuate nucleus, 
which secrete neuropeptide Y (NPY) and -melanocyte-stimulating hormone (-
MSH), playing a role in the regulation of food intake. PACAP is expressed in nerve 
fibers of the suprachiasmatic nucleus (SCN) of the hypothalamus corresponding to the 
projection of the retinohypothalamic tract and in nerve fibers in the pineal gland, 
thereby regulating circadian rhythmicity. PACAP is also expressed in cells of the 
preoptic nucleus, which play an important role in the regulation of body temperature 
(Hannibal, 2002).  
 PACAP‟s widespread central expression suggests a regulatory role in various 
physiological and behavioral processes. This is supported by the phenotypes of 
PACAP- and PACAP receptor-deficient mice. PACAP- and PAC1-deficient mice 
show altered psychomotor behaviors, such as increased locomotor activity in novel 
environments and reduced anxiety-like behavior, abnormal social behavior, and 
impairments in hippocampal long-term potentiation (LTP) and learning and memory 
(Hashimoto et al., 2006; Hashimoto et al., 2001; Matsuyama et al., 2003; Nicot et al., 
2004; Otto et al., 2001a; Otto et al., 2001b). 
1.3.4.3 Neurotrophic and cytoprotective functions 
In the developing nervous system, PACAP functions as a neurotrophic factor 
promoting cell survival and neurite outgrowth in a variety of cell types, including 
cerebellar granule cells (Gonzalez et al., 1997; Vaudry et al., 2000a), cortical 
neuroblasts (Lu and DiCicco-Bloom, 1997) and dorsal root ganglion neurons 
(Lioudyno et al., 1998). PACAP also promotes survival and regeneration in the 
mature nervous system and inhibits apoptotic cell death under paraphysiological and 
pathophysiological conditions, such as stroke (Brenneman, 2007; Waschek, 2002). In 
vivo, endogenous and exogenous PACAP reduce infarct volume and ameliorate 
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neurological defects after permanent middle cerebral artery occlusion (pMCAO) 
(Chen et al., 2006; Ohtaki et al., 2006; Reglodi et al., 2002; Tamas et al., 2002). 
PACAP reduces the effect of focal and global transient ischemia even when given up 
to several hours post-insult (Reglodi et al., 2000; Stetler et al., 2010; Uchida et al., 
1996). Moreover, PACAP crosses the blood-brain-barrier (BBB) via saturable peptide 
transport and has neuroprotective effects after ischemia not only when administered 
intracerebroventricularly (i.c.v.) but also when given intravenously (i.v.) (Banks et al., 
1993; Banks et al., 1996). PACAP is also protective in other neurodegenerative 
conditions, e.g., in association with Parkinson‟s (Reglodi et al., 2006; Reglodi et al., 
2004) and Alzheimer‟s disease (Kojro et al., 2006; Rat et al., 2011). In cell culture, 
PACAP promotes the survival of cultured cortical neurons under hypoxic/ischemic 
and excitotoxic conditions (Frechilla et al., 2001; Morio et al., 1996; Nowak et al., 
2007; Pellegri et al., 1998; Said et al., 1998; Shintani et al., 2005; Stumm et al., 2007). 
Multiple other cell types are protected by PACAP under a variety of conditions that 
promote apoptosis. Specifically, PACAP ameliorates cell death in hippocampal 
cultures exposed to the HIV envelope protein gp120 (Arimura et al., 1994) and in 
cerebellar granule cells incubated in low-potassium or serum-free medium, or 
exposed to ethanol or oxidative stress (Cavallaro et al., 1996; Kienlen Campard et al., 
1997; Tabuchi et al., 2003; Vaudry et al., 2002b; Vaudry et al., 2002c; Villalba et al., 
1997). Serum and NGF withdrawal-induced cell death in differentiated PC12 cells 
(Tanaka et al., 1997) and primary sympathetic neurons (May et al., 2010) is reduced 
by PACAP. PACAP also rescues motoneurons (Tomimatsu and Arakawa, 2008), 
retinal neurons (Shoge et al., 1999) and PC12 cells (Onoue et al., 2002b) from 
glutamate-induced excitotoxicity. 
 PACAP‟s neuroprotective effects during glutamate-induced excitotoxicity in 
cortical neurons (Morio et al., 1996; Said et al., 1998) and during K
+
 and serum 
deprivation and hydrogen peroxide exposure of cerebellar granule neurons (Cavallaro 
et al., 1996; Vaudry et al., 2002b) are mimicked by intracellular cAMP production, 
suggesting that PACAP mediates its effects via a cAMP dependent signaling pathway. 
Activation of PKA (Kienlen Campard et al., 1997; Shoge et al., 1999; Tanaka et al., 
1997; Tomimatsu and Arakawa, 2008; Vaudry et al., 1998b) and ERK1/2 (May et al., 
2010; Pugh and Margiotta, 2006; Vaudry et al., 2002b; Villalba et al., 1997) have 
been implicated in mediating PACAP‟s neuroprotective effects in various cell types 
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under diverse conditions promoting apoptosis. PACAP-mediated neuritogenesis in 
PC12 cells can occur via PKA dependent (Hernandez et al., 1995) and PKA 
independent but cAMP and ERK1/2 dependent (Ravni et al., 2008) signaling 
pathways. 
 It has been suggested that PACAP mediates its neuroprotective effects via 
direct and indirect mechanisms (Dejda et al., 2011). The activation of PKA (Shoge et 
al., 1999; Stetler et al., 2010; Tanaka et al., 1997) and ERK1/2 (May et al., 2010; 
Pugh and Margiotta, 2006; Stumm et al., 2007; Villalba et al., 1997) and the 
inhibition of caspase-3 (Dejda et al., 2008; Onoue et al., 2002a; Vaudry et al., 2002b) 
have been shown to be directly involved in PACAP-mediated prevention of neuronal 
apoptosis induced by various insults. PACAP also suppresses cell death via BDNF 
gene induction in cortical neurons exposed to excitotoxicity (Frechilla et al., 2001). 
Indirectly, PACAP may mediate neuroprotection via modulation of glial cells, such as 
astroglia (Stumm et al., 2007) and microglia (Armstrong et al., 2008; Delgado et al., 
2003b) to provide neurotrophic support and control of the inflammatory response, 
respectively. PACAP-induced astroglial IL-6 release (Gottschall et al., 1994) has been 
implicated in PACAP‟s neuroprotective effects during ischemia in vivo (Ohtaki et al., 
2006). 
1.4 Stanniocalcin 1 (STC1), a potential mediator of PACAP’s 
cytoprotective effects 
STC (previously called teleocalcin) was originally identified in bony fish, where it is 
secreted from the corpuscules of Stannius (a kidney-associated specialized gland) in 
response to increased extracellular calcium levels, regulating calcium and phosphate 
homeostasis and protecting against toxic hypercalcemia (Wagner et al., 1989; Wagner 
and Jaworski, 1994). Specifically, STC reduces plasma [Ca
2+
] by inhibiting calcium 
uptake through gills (Wagner et al., 1986) and gut (Sundell et al., 1992) and 
stimulates renal phosphate (Pi) reabsorption through a cAMP and PKA dependent 
pathway (Lu et al., 1994). For almost ten years, STC was considered to be a 
polypeptide hormone with calcitonin- and parathyroid hormone (PTH)-like properties 
unique to fish (Gerritsen and Wagner, 2005). Its discovery in mammals and molecular 
cloning revealed that STC is highly conserved through vertebrate evolution, 
especially within its N-terminal and core region (Chang et al., 1996; Chang et al., 
  Introduction 
14 
 
1995; Wagner et al., 1995). A second STC protein with 30% sequence homology to 
STC1 has been identified, first in mammals and subsequently in fish (Chang and 
Reddel, 1998; Luo et al., 2005). STC1 is a ~28-kDa glycoprotein that exists as a 56-
kDa homodimer; no significant homology to other known proteins or previously 
identified motifs has been detected to date. A notable feature of STC1 are its 11 
cysteine residues, of which the first ten form five intramolecular disulfide bonds and 
the last one forms an interchain disulfide linkage creating a homodimer (Trindade et 




Figure 5: Amino acid sequence and predicted secondary structure of human STC1. The 
primary translation product is 247 residues and 25 kDa. Different regions from N- to C-
terminus: signal peptide: 1-28 (purple), pro-peptide: 19-33 (gray), mature protein: 34-247 
(black). 11 cysteine residues (red) give rise to five intramolecular disulfide bridges (indicated 
by black horizontal brackets) and one interchain disulfide linkage, creating a homodimer. N-
linked glycosylation (green) at the site of the type N-X-T/S adds ~3 kDa. Below the sequence 
is a schematic representation of the predicted secondary structure: red: alpha helix, yellow: 
beta sheet, green: coil region, black: not assigned (modified from Trindade et al., 2009). 
 In mammals, STC1 is expressed in many tissues, in contrast to its localized 
glandular expression in fish, suggesting an autocrine/paracrine rather than an 
endocrine function extending beyond the regulation of mineral metabolism (De Niu et 
al., 2000). The highest level of expression is seen in adult ovaries, where STC1 exists 
as three higher molecular proteins of 84, 112 and 135 kDa. All three “big STCs” are 
chemically reduced to one 45 kDa protein (Paciga et al., 2002). STC1 of 56 kDa is, 
among other tissues, expressed in kidney, adrenal, heart, lung, thymus, brain and 
developing bone. STC1 protein can accumulate in tissues through receptor-mediated 
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sequestration. Subcellularly, it is targeted to mitochondria in nephron cells and liver 
hepatocytes, increasing respiration rate (Ellard et al., 2007; McCudden et al., 2002), 
and to other organelles such as lipid storage droplets (LSD) in adipocytes and 
steroidogenic cells (Paciga et al., 2003) or the nucleus in lactating mammary gland 
alveolar cells (Hasilo et al., 2005). Within the kidney, STC1 stimulates Pi 
reabsorption, consistent with its function in fish (Wagner et al., 1997). 
STC1 is upregulated during neuronal differentiation (Zhang et al., 1998) and 
in neurons of the ischemic penumbra (i.e., ischemic but still viable cerebral tissue), 
presumably supporting neuronal survival (Zhang et al., 2000). In cell culture, STC1 
increases cell resistance to hypoxic and hypercalcemic insult (Zhang et al., 2000). 
Induction of STC1 after neuronal and myocardial hypoxic preconditioning, conferring 
resistance to further ischemic damage, is dependent on IL-6 (Westberg et al., 2007a; 
Westberg et al., 2007b). STC1 is a PACAP-regulated gene, as shown in chromaffin 
cells of the adrenal medulla by our laboratory (Ait-Ali et al., 2010), potentially 
mediating PACAP‟s neurotrophic and cytoprotective effects. STC2 is also induced by 
various stressors, contributing to cell survival; however, its induction is, unlike that of 
STC1, dependent on the unfolded protein response (UPR) activated by endoplasmic 
reticulum (ER) stress (Ito et al., 2004).  
STC1 and STC2 transgenic mice exhibit altered mineral homeostasis, higher 
rates of metabolism, reduced female fertility and growth retardation (Filvaroff et al., 
2002; Gagliardi et al., 2005; Varghese et al., 2002). STC1-, STC2- and STC1/2-null 
mice, however, show no changes in mineral homeostasis, fertility or development. 
Increased postnatal growth in STC2- and STC1/2-null mice is the only detected 
phenotype so far (Chang et al., 2005; Chang et al., 2008). 
1.5 Aims 
As outlined above, PACAP‟s effects in the central and peripheral nervous system are 
mainly mediated by its cognate G protein-coupled receptor PAC1. The predominant 
variants are the receptors with the hop cassette (PAC1hop) or no cassette (PAC1null) 
in the third intracellular loop (ic3) and a full-length N-terminus. Receptors containing 
a hip cassette (PAC1hip) are less abundant. Although the different ic3 splice variants 
were first discovered almost 20 years ago, an understanding of the signaling pathways 
used by these different variants in neural and neuroendocrine cells is still lacking. 
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Moreover, whether these variants mediate different functional outcomes, specifically 
under paraphysiological conditions, such as prolonged stress, is not clear. 
Therefore, the aim of the present study was to investigate the induction of the 
second messengers cAMP and Ca
2+
 by the PAC1hop, null and hip receptor variants 
with a full-length N-terminus in neural and neuroendocrine cell lines through over-
expression of the respective receptor variants. Moreover, the signal transduction 
pathway mediating the induction of STC1, a gene potentially involved in PACAP‟s 
neuroprotective effects in vivo, was characterized. The biological significance of 
mammalian STC1 still remains elusive. Elucidation of its gene regulation will give 
important information towards understanding its function in vivo. Experiments from 
heterologous expression systems were extended to primary cortical neurons. The 
detailed aims were the following: 
 
(1) Characterization of PAC1 splice variant-specific signaling mediating sustained 
catecholamine secretion from neuroendocrine cells 
To determine PAC1 splice variant-specific signaling in neuroendocrine cells, the three 
main splice variants in the mature nervous system, the PAC1hop1, null and hip 
variant with a full-length N-terminus, were expressed in the rat pheochromocytoma 
PC12-G cell line. The intracellular Ca
2+
 response and catecholamine secretion, in 
particular sustained secretion was investigated to give new insight into the 
mechanisms by which PACAP induces long-term secretion from adrenomedullary 
chromaffin cells in vivo to restore homeostasis during periods of prolonged stress. 
 
(2) Characterization of PAC1 splice variant-specific signaling in neural cells of the 
central nervous system and the signaling pathways mediating STC1 gene 
induction 
The three PAC1 variants were expressed in the mouse neuroblastoma x rat glioma 
NG108-15 cell line and the intracellular cAMP and Ca
2+
 responses measured. 
Moreover, signaling pathways mediating ERK1/2 activation and STC1 induction were 
investigated to provide preliminary information about the regulation of the putative 
neuroprotectant STC1 in the central nervous system. 
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(3) Establishing the signaling pathways mediating STC1 gene induction in primary 
neurons, potentially mediating PACAP dependent ischemic stress responses in 
vivo 
To extend results obtained from heterologous expression systems, signaling pathways 
mediating STC1 gene induction were investigated in primary cultures of differentiated 
rat cortical neurons. Elucidation of STC1 gene induction in primary neurons was used 
to provide important insights in its regulation in vivo, helping to identify how PACAP 
mediates its neuroprotective effects in neurodegenerative disorders, such as stroke. 
 
(4) Effects of PACAP and the PACAP target gene STC1 in neuroprotection 
Neuroprotective effects of PACAP in conditions associated with stroke were studied 
in primary rat cortical neurons. Moreover, STC1 was over-expressed in neurons to 
study its role in neuroprotection to provide mechanistic insights into how PACAP 
mediates its neuroprotective effects during stroke in vivo. 





(+)-MK-801 hydrogen maleate Sigma, St. Louis, MO 
0.25% Trypsin-EDTA Gibco, Carlsbad, CA 
2ʹ5ʹ-Dideoxyadenosine, 1 mg CalBiochem, San Diego, CA 
2ʹ5ʹ-Dideoxyadenosine, 5 mg Sigma, St. Louis, MO 
3(4,5-dimethylthiazolyl-2)2,5-diphenyl- 
tetrazoliumbromide Sigma, St. Louis, MO 
3-isobutyl-1-methylxanthine (IBMX) Sigma, St. Louis, MO 
Acetic acid glacial Chempure, New York, NY 
Agarose Invitrogen, Carlsbad, CA 
Ampicillin sodium salt Sigma, St. Louis, MO 
Ascomycin Sigma, St. Louis, MO 
B-27 serum-free supplement, 50X Gibco, Carlsbad, CA 
BAPTA, AM Invitrogen, Carlsbad, CA 
Bisbenzimide Hoechst 33342 Sigma, St. Louis, MO 
Bisindolylmaleimide I Sigma, St. Louis, MO 
BSA Santa Cruz Biotechnology, Santa Cruz, CA 
Cocktail inhibitor tablet Roche Applied Science, Mannheim, Germany 
Cyclosporin A Sigma, St. Louis, MO 
DEPC treated water Quality Biological Inc., Gaithersburg, MD 
Dexamethasone Sigma, St. Louis, MO 
Dimethyl sulfoxide (DMSO) Sigma, St. Louis, MO 
Dimethylformamide (DMF) Sigma, St. Louis, MO 
DMEM 1X, high glucose Gibco, Carlsbad, CA 
EDTA, 0.5 M Mediatech Inc., Herndon, VA 
Ethidium bromide solution Invitrogen, Carlsbad, CA 
Fetal bovine serum (FBS) Gibco, Carlsbad, CA 
Filter Paper Sandwich (0.45µm pore size) Invitrogen, Carlsbad, CA 
Forskolin, Coleus forkohlii CalBiochem, San Diego, CA 
Fura-2 AM Molecular Probes, Eugene, OR 
G418, Geneticin Gibco, Carlsbad, CA 
Gene Amp 10 mM dNTP Mix with dTTP Applied Biosystems, Carlsbad, CA 
GeneRuler DNA ladders (100 bp and 1 kb) Fermentas, Glen Burnie, MD 
Glycerol Sigma, St. Louis, MO 
H-89, Dihydrochloride CalBiochem, San Diego, CA 
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Halt phosphatase inhibitor cocktail Thermo Scientific, Rockford, IL 
HAT supplement, 50X Gibco, Carlsbad, CA 
HEPES, 1 M Gibco, Carlsbad, CA 
Hoechst 33342 Sigma, St. Louis, MO 
Horse Serum Cambrex, East Rutherford, NJ 
iQ SYBR Green Supermix Bio-Rad, Carlsbad, CA 
Levo-7[
3
H]-Norepinephrine PerkinElmer, Waltham, MA 
L-Glutamic acid Sigma, St. Louis, MO 
L-glutamine, 200 mM Gibco, Carlsbad, CA 
Magic Mark XP Western Standard Invitrogen, Carlsbad, CA 
Methanol Fisher Scientific, Pittsburgh, PA 
Neurobasal medium Gibco, Carlsbad, CA 
Neurobasal-A medium without glucose Gibco, Carlsbad, CA 
Neurobasal-A medium Gibco, Carlsbad, CA 
Nitric acid Sigma, St. Louis, MO 
NMDA Sigma, St. Louis, MO 
Norepinephrine, levo-[7-
3
H]- PerkinElmer, Waltham, MA 
NuPAGE LDS sample buffer Invitrogen, Carlsbad, CA 
NuPAGE MOPS SDS Running Buffer Invitrogen, Carlsbad, CA 
NuPAGE Reducing agent, 10X Invitrogen, Carlsbad, CA 
NuPAGE transfer buffer Invitrogen, Carlsbad, CA 
NuPAGE transfer buffer, 20X Invitrogen, Carlsbad, CA 
PACAP(6-38) Phoenix Pharmaceuticals, Mountain View, CA 
PACAP38 (Human, Ovine, Rat) Phoenix Pharmaceuticals, Mountain View, CA 
Penicillin-Streptomycin Gibco, Carlsbad, CA 
Poly-L-lysine hydrobromide, mol wt >300,000 Sigma, St. Louis, MO 
Ponceau S Sigma, St. Louis, MO 
Propidium Iodide Sigma, St. Louis, MO 
Puromycin, DiHCl, Cell Culture-T CalBiochem, San Diego, CA 
Restore Western Blot Stripping Buffer Thermo Fisher Scientific, Rockford, IL 
See blue Plus 2 Prestained Standard 1x Invitrogen, Carlsbad, CA 
SOC Quality Biological Inc., Gaithersburg, MD 
Sodium chloride, 5 M Quality Biological Inc., Gaithersburg, MD 
Sodium Dodecyl Sulfate (SDS) Bio-Rad, Carlsbad, CA 
Super Signal West Pico Chemiluminescence Substrate Thermo Fisher Scientific, Rockford, IL 
TAE Quality Biological Inc., Gaithersburg, MD 
TrackIt DNA ladder (100 bp) Invitrogen, Carlsbad, CA 
Tris-HCl Quality Biological Inc., Gaithersburg, MD 
Triton X-100 Sigma, St. Louis, MO 
Tween 20 Sigma, St. Louis, MO 
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U0126 CalBiochem, San Diego, CA 
U-73122 CalBiochem, San Diego, CA 
U-73343 CalBiochem, San Diego, CA 
Ultima Gold 
TM
 (high flash-point LSC cocktail) PerkinElmer, Waltham, MA 
2.2 Enzymes and inhibitors 
Ampli Taq Gold DNA Polymerase (5U/µl) Applied Biosystems, Carlsbad, CA 
Calf intestinal alkaline phosphatase (CIP) New England Biolabs, Ipswich, MA 
DNase I (D4527) Sigma, St. Louis, MO 
DNase I recombinant, RNase-free (10U/µl) Roche Applied Science, Mannheim, Germany 
NEBuffer for Restriction Endonucleases New England Biolabs, Ipswich, MA 
Restriction Endonucleases New England Biolabs, Ipswich, MA 
Restriction Endonucleases Roche Applied Science, Mannheim, Germany 
RNase inhibitor Invitrogen, Carlsbad, CA 
Superscript II RT Invitrogen, Carlsbad, CA 
SuRE Cut Buffers for Restriction Endonucleases Roche Applied Science, Mannheim, Germany 
T4 DNA ligase Roche Applied Science, Mannheim, Germany 
T4 DNA Polymerase Invitrogen, Carlsbad, CA 
2.3 Kits 
cAMP Biotrak Enzymeimmunoassay (EIA) System Amersham Biosciences 
DC protein assay Bio-Rad, Hercules, CA 
Plasmid Maxi Kit Qiagen, Valencia, CA 
ProFection Mammalian Transfection System Kit Promega, Madison, WI 
QIAprep Spin Miniprep Kit Qiagen, Valencia, CA 
QIAquick Gel Extraction Kit Qiagen, Valencia, CA 
Rapid DNA Ligation Kit Roche Applied Science, Mannheim, Germany 
RNeasy Mini Kit Qiagen, Valencia, CA 
TOPO TA Cloning Kit (pCR2.1-TOPO Vector) Invitrogen, Carlsbad, CA 
Wizard DNA clean-up system Promega, Madison, WI 
2.4 Antibodies 
Goat Ant-Rabbit IgG, Peroxidase Conjugated Thermo Scientific, Rockford, IL 
p44/42 MAPK (Erk1/2) Cell Signaling Technology, Beverly, MA 
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) Cell Signaling Technology, Beverly, MA 




Oligonucleotides were selected based on sequences published in PrimerBank 
(http://pga.mgh.harvard.edu/primerbank/) or designed with Primer3 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi) and tested with the PCR 
primer stats feature of the sequence manipulation suite 
(http://www.bioinformatics.org/sms2/). Nucleotide sequences were tested for 
homologous sequences using BLAST (Basic Logical Alignment Tool) 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The design was based on length (18-26 
bases), guanine and cytosine (GC) content (40-60%) and melting temperature (55-
70°C). Moreover, the presence of more than one G or C in the last five bases was 
favored. Oligonucleotides that had more than three self-annealing bases in a row or 
lead to the formation of hairpins were excluded. All oligonucleotides were 
synthesized by Integrated DNA Technologies (IDT). 
 










 GAG AGA AGG CGA ATA CTG TG 187 or 271 
PAC1hop R 
b




 TGG GGA CTC TCA GTC TTA AA 142 Z23273.1 
VPAC1 F GCA GCA ACA GAC CAA GTT CTA C  NM_012685.2 and 
NM_011703.4 VPAC1 R TGA ACA GGC TCA AGA TAG CCA T 107 
VPAC2 F AAG CAA AAA CTG CAC TAG TGA  NM_017238.1 and 
NM_009511.2 VPAC2 R GCC CAA GGT ATA AAT GGC CTT CA 133 
GAPDH F GTT ACC AGG GCT GCC TTC TC  NM_017008.3 and 
NM_008084.2 GAPDH R GGG TTT CCC GTT GAT GAC C 168 
STC1 F CTA CTT TCC AGA GGA TGA TCG C  NM_031123.2 and 
NM_009285.3 STC1 R ACT TCA GTG ATG GCT TCC GG 100 
STC2 F GTC ACC CGA AGC GTC CAG GCT  NM_022230.1 and 
NM_011491.3 STC2 R TCC CTC GCT CAC CCT TGG CA 208 
BDNF F TCA TAC TTC GGT TGC ATG AAG G  NM_012513.3 and 
NM_007540.4 BDNF R AGA CCT CTC GAA CCT GCC C 137 
All primers were designed to match the respective rat and mouse sequences. 
 




 The PAC1 forward primer was used in combination with all PAC1 reverse primers. 
PAC1 F matches the beginning of transmembrane region five (TM 5) corresponding 
to bases 1018 to 1037 of the rat PAC1null sequence Z23279. PAC1 R matches the 
end of TM 6 corresponding to bases 1185 to 1204 of the rat PAC1null sequence 
Z23279. PAC1hop R matches the end of the hop cassette corresponding to bases 
1193-1217 of the rat PAC1hop1 sequence Z23274. PAC1hip R matches the beginning 
of the hip cassette corresponding to bases 1140-1159 of the rat PAC1hip sequence 
Z23273. PAC1 F/PAC1 R generates a 187- or 271-bp fragment, depending on 
whether or not a hip- or hop-insert is present. 
2.6 Plasmids 
pBluescript II KS (+)-STC1 Gopal Thinakaran, Univ. of Chicago 
pLVX-IRES-ZsGreen1 Clontech, Mountain View, CA 
pPRIG Patrick Martin, Univ. of Nice 
pPRIG-rPAC1null, hop1 and hip Tomris Mustafa, NIH 
2.7 Buffers and solutions 
KRB 20 mM HEPES 
 5.5 mM glucose 
 125 mM NaCl 
 5 mM KCl 
 1 mM Na2HPO4 
 1 mM MgSO4 




-free KRB 20 mM HEPES 
 5.5 mM glucose 
 125 mM NaCl 
 5 mM KCl 
 1 mM Na2HPO4 
 1 mM MgSO4 
 100 µM EGTA 
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WB lysis buffer 1X NuPAGE LDS sample buffer 
 1X NuPAGE reducing agent 
 1X cocktail inhibitor tablet 
 1X Halt phosphatase inhibitor cocktail 
 
Ponceau S solution 0.1% Ponceau S 
 5% acetic acid glacial 
 
TBS 50 mM Tris-HCl (pH 8) 
 150 mM NaCl 
 
TBST 50 mM Tris-HCl (pH 8) 
 150 mM NaCl 
 0.1% Tween 20 
 
WB blocking buffer TBST 
 5% skim milk 
 
WB transfer buffer 1X NuPAGE transfer buffer 
 10% Methanol 
2.8 Cell culture media 
293T cells DMEM 1X, high glucose supplemented with: 
 10% FBS, heat-inactivated 
 2 mM L-glutamine 
 100 U/ml penicillin and 100 µg/ml streptomycin 
 
PC12-G cells DMEM 1X, high glucose supplemented with: 
 7% FBS, heat-inactivated 
 7% Horse serum 
 2 mM L-glutamine 
 25mM HEPES 
 100 U/ml penicillin and 100 µg/ml streptomycin 




NG108-15 cells DMEM 1X, high glucose supplemented with: 
 10% FBS, heat-inactivated 
 2 mM L-glutamine 
 1X HAT 





 DMEM 1X, high glucose supplemented with: 
 10% FBS, heat-inactivated 





 Neurobasal medium supplemented with: 
 1X B-27 serum-free supplement 
 0.5 mM L-glutamine 
 25 µM L-glutamate 
 
OGD medium Glucose-free Neurobasal-A medium supplemented with: 
 1X B-27 serum-free supplement 
 0.5 mM L-glutamine 
 
Heat-inactivation of FBS for 30 min at 56°C 
2.9 Cells 
HEK 293T cells Cell Genesys Inc., Foster City, CA 
MAX Efficiancy DH5α competent cells Invitrogen, Carlsbad, CA 
NG108-15 cells ATCC, Manassas, VA 
PC12-G cells (Greene and Tischler, 1976) 
PC12-bPAC1hop cells (Mustafa et al., 2007) 
2.10 Animals 
Wistar rats (17 days pregnant) were purchased from Charles River, Wilmington, MA 




C24 incubator shaker New Brunswick Scientific, Edison, NJ 
Centrifuge 5415C Eppendorf 
Centrifuge 5810 Eppendorf 
Centrifuge RC5C Plus Sorvall 
Cetus DNA Thermal Cycler PerkinElmer, Waltham, MA 
Dual-Intensity Transilluminator UVP 
FluorChem 8800 Imaging System Alpha Innotech 
iCycler iQ Real Time PCR System Bio-Rad, Carlsbad, CA 
Image Station 440CF Kodak 
Isotemp Waterbath Thermo Fisher Scientific 
LS 6500 Scintillation Counter Beckman Coulter, Brea, CA 
Microscope IX70 Olympus 
NanoVue Spectrophotometer GE Healthcare, Piscataway, NJ 
Nikon Eclipe Ti inverted microscope Nikon instruments 
PTC-225 Peltier Thermal Cycler MJ Research 
Rotors SLA-1500/3000 Sorvall 
SpectraMax 340 Microplate Reader Molecular Devices 
The Belly Dancer Stovall Life Science Inc., Greensboro, NC 
Ultrasonic processor GE 130PB Hielscher, Ringwood, NJ 
XCELLII Blot Module (E19051) Invitrogen, Carlsbad, CA 
2.12 Software 
ImageJ public domain 
iVision BioVision Technologies, Exton, PA 
MetaFluor Molecular Devices, Silicon Valley, CA 
NIS Elements Nikon Instruments, Melville, NY 
Prism 4 GraphPad Software, La Jolla, CA 
2.13 Other supplies 
0.45 μm syringe filter Millipore, Bedford, MA 
10-cm dish Becton Dickinson, Franklin Lakes, NJ 
162 cm
2
 cell culture flask Corning Incorporated, Corning, NY 
75 cm
2
 cell culture flask Becton Dickinson, Franklin Lakes, NJ 
Amicon Ultra-15 Centrifugal Filter Units Millipore, Bedford, MA 
Cryotube vial Thermo Scientific, Rockford, IL 
Falcon tube Becton Dickinson, Franklin Lakes, NJ 
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Glass cover slips (diameter 1.5 cm) Assistent, Sondheim/Rhoen, Germany 
Multiple well culture plates Corning Incorporated, Corning, NY 
NuPAGE Novex Pre-Cast 4-12% Bis-Tris Gel Invitrogen, Carlsbad, CA 
Skim milk Bio-Rad, Hercules, CA 
Sponge pads Invitrogen, Carlsbad, CA 




3.1 Cell culture 
3.1.1 Culture and propagation of PC12-G cells 
PC12-G cells, derived from a rat adrenal pheochromocytoma (Greene and Tischler, 
1976) were obtained from the laboratory of Dr. Gordon Guroff at NIH (Rausch et al., 
1988) and cultured in 1X Dulbecco‟s modified Eagle‟s medium (DMEM) High 
Glucose (4.5 g/L D-Glucose) supplemented with 7% heat-inactivated (56ºC for 30 
min) fetal bovine serum, 7% horse serum, 25 mM HEPES, penicillin-streptomycin 
(100 U/ml penicillin and 100 µg/ml streptomycin) and 2 mM L-glutamine under 90% 
air and 10% CO2. Cells were grown in 75 or 162 cm
2
 cell culture flasks and passaged 
at approximately 80% cell density. Cells were mechanically dislodged by vigorous 
tapping and centrifuged for 5 min at 300 x g. Cells were resuspended in 10 ml fresh 
medium and triturated extensively before counting and replating to avoid the 
formation of cell aggregates. The cell suspension was triturated up to 10 times by 
passage through a 10-ml pipette fitted with a yellow (200 μl) pipette tip. 
For experiments, cells were plated at a density of 100,000 cells/ 0.95 cm
2
 
growth area on poly-L-lysine-coated (0.1 mg/ml) multiple well culture plates and 
allowed to adhere overnight. 
3.1.2 Culture and propagation of NG108-15 cells 
NG108-15 cells (mouse neuroblastoma x rat glioma hybrid), obtained from the 
American Type Culture Collection (ATCC) were cultured in 1X DMEM High 
Glucose (4.5 g/L D-Glucose) supplemented with 10% heat-inactivated fetal bovine 
serum, penicillin-streptomycin (100 U/ml penicillin and 100 µg/ml streptomycin), 2 
mM L-glutamine and 1X HAT (hypoxanthine, aminopterine, thymidine; for 
nucleotide synthesis via the salvage pathway) to maintain hybrid selection under 95% 
air and 5% CO2. Cells were grown in 75 or 162 cm
2
 cell culture flasks and passaged at 
approximately 80% cell density. Cells were mechanically dislodged by vigorous 
tapping, centrifuged for 5 min at 150 x g and resuspended in 10 ml fresh medium. 
  Methods 
28 
 
For experiments, cells were plated at a density of 30,000 cells/ 0.95 cm
2
 
growth area on poly-L-lysine-coated (0.1 mg/ml) multiple well culture plates and 
allowed to adhere overnight. 
3.1.3 Culture and propagation of 293T cells 
The human embryonic kidney (HEK) 293T cell line was cultured in 1X DMEM High 
Glucose (4.5 g/L D-Glucose) supplemented with 10% heat-inactivated fetal bovine 
serum, penicillin-streptomycin (100 U/ml penicillin and 100 µg/ml streptomycin) and 
2 mM L-glutamine under 95% air and 5% CO2. Cells were grown in 75 cm
2
 cell 
culture flasks and passaged at approximately 80% cell density. Cells were washed 
once with 5 ml PBS and incubated in 1 ml 0.25% Trypsin-EDTA until cells were 
detached (after ~3 min). 9 ml medium was added and cells were resuspended. 
For transfection experiments, 2 x 10
6
 cells were plated in poly-L-lysine-coated 
(0.1 mg/ml) 10-cm dishes (in 10 ml) and allowed to adhere overnight. 
3.1.4 Preparation of frozen cell stocks 
Frozen stocks of low passage numbers were stored in liquid nitrogen and prepared by 
resuspending ~25 x 10
6
 PC12-G cells, ~6 x 10
6
 NG108-15 cells or ~20 x 10
6
 293T 
cells in 1 ml cold complete medium containing 5% (PC12-G cells) or 7.5% (NG108-
15 and 293T cells) dimethyl sulfoxide (DMSO). The cell suspension was transferred 
to a cryostat vial, stored overnight at -80°C in an insulated container before transfer to 
liquid nitrogen. Cells were thawed in a 37°C water bath (no more than 1 min), 
transferred to a 50 ml Falcon tube containing 9 ml complete medium and centrifuged 
for 5 min at 300 x g (PC12-G cells) or 150 x g (NG108-15 and 293T cells). Cells 
were resuspended in medium and transferred to a 75 cm
2
 cell culture flask. Cells were 
passaged at least once before being used in experiments and used between passage 
seven and 25. 
3.1.5 Preparation and culture of primary rat cortical neurons 
Rat cortical neurons were prepared from cortices of embryos from 18-day-pregnant 
Wistar rats. Pregnant animals were killed by exposure to CO2 and embryos were 
extracted. After extracting the embryonic brains, the cortices were dissected and 
placed in Neurobasal medium supplemented with 1X B27, 500 µM L-glutamine and 
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25 µM L-glutamate (complete Neurobasal medium). Cortices were triturated in 
complete Neurobasal medium containing 50 µg/ml DNase and 0.25% Trypsin. After a 
15-min-incubation, 30% horse serum was added and cells were triturated again. Cells 
were washed twice with complete Neurobasal medium and resuspended in 1X 
DMEM High Glucose (4.5 g/L D-Glucose) supplemented with 10% FBS and 2 mM 
L-glutamine. Following filtration, cells were plated at a density of 125,000 cells/ 0.95 
cm
2
 growth area on poly-L-lysine-coated (0.1 mg/ml) plates. The medium was 
changed after one day in culture to complete Neurobasal medium. Cells were kept 
under 95% air and 5% CO2 and used after 8-13 days in culture. 
3.1.6 Coating of cell culture plates 
Multiple well culture plates and 10-cm dishes were coated with 0.1 mg/ml poly-L-
lysine (PLL). Dishes were incubated with PLL for 1 to 16 h, washed three times with 
PBS and dried overnight. For the viability of cortical cultures, it was crucial to 
incubate the dishes with PLL solution for at least 6 h. 
3.1.7 Growth area of multiple well culture plates 
The growth area per well is 9.5 cm
2
 for 6-well, 3.8 cm
2





 for 48-well and 0.32 cm
2
 for 96-well plates. 
3.2 Virus production and infection of cells 
3.2.1 Production of gammaretroviral particles and infection of PC12-G and 
NG108-15 cells 
Retroviral vectors were produced by a three-plasmid co-transfection of 293T cells 
with the calcium phosphate method (ProFection Mammalian Transfection System Kit, 
Promega) according to the manufacturer‟s instructions. The retroviral vector encoding 
self-inactivating (SIN) 3ʹ-long terminal repeat (LTR) regions together with the 
transgene targeted for genomic integration was co-transfected with plasmids encoding 
transcripts for packaging proteins (gag/pol and env). 
293T cells were plated in 10-cm dishes and incubated overnight (see 3.1.3). 
Three hours before transfection the medium was replaced with 10 ml fresh medium. 
10 μg of the bicistronic retroviral vector pPRIG (plasmid Polylinker Retroviral IRES 
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GFP) (Martin et al., 2006) expressing the respective PAC1 receptor (rat PAC1null, 
hop1 and hip with a full-length N-terminus, which were subcloned from pRK8 
vectors (Spengler et al., 1993) into the EcoRI/SalI sites of pPRIG) and the tracer 
enhanced green fluorescent protein (eGFP) from a unique cytomegalovirus (CMV) 
promoter, together with the Murine Leukemia Virus (MuLV)-based gag/pol plasmid, 
pIK6MuLVgp (2.5 μg), and a VSV-G envelope plasmid (5 μg) were co-transfected 
and incubated overnight. The medium was replaced with 5.5 ml fresh medium and 
retroviral vector-containing supernatant was harvested 48 h post-transfection. 5.5 ml 
fresh medium was added and the second supernatant was harvested 24 h later. The 
supernatant was filtered through a 0.45 µm syringe filter and used for infection of 
PC12-G and NG108-15 cells. Aliquots were stored at -80°C. 
To generate cell lines stably expressing the PAC1 receptor variants null, hop1 
and hip, PC12-G (3.1.1) or NG108-15 cells (3.1.2) were plated onto 12-well plates 
and incubated overnight. Before infection, the medium was removed and 0.5 ml fresh 
medium and 0.5 ml virus preparation was added. After overnight incubation, the 
medium was changed. Transduction efficiency of the PAC1 receptor variants was 
determined by direct visualization of eGFP, expressed from its IRES-dependent 
cistron. 
3.2.2 Production of lentiviral particles and infection of primary rat cortical 
neurons 
Lentiviral vectors can be used for transducing non-dividing mammalian cells, such as 
neurons and were generated according to the protocol used for production of 
gammaretroviral particles (3.2.1) with the following modifications: 10 µg of the 
bicistronic lentiviral expression vector pLVX-IRES-ZsGreen1 (Clontech) co-
expressing stanniocalcin 1 (which was subcloned from pBluescript II KS (+)-STC1 
(G. Thinakaran; XbaI/Asp718 blunted) into the XbaI/EcoRI blunted sites of pLVX) 
from a CMV promoter and simultaneously the tracer ZsGreen1 from its IRES 
dependent cistron were co-transfected with plasmids expressing gag/pol/rev (6.5 µg) 
and VSV-G envelope (3.5 µg). The combined 48- and 72-h supernatant was filtered 
and concentrated 50-fold through ultrafiltration (Amicon Ultra-15 Centrifugal Filter 
Units) for 15 min at 3,500 x g at 4°C. The concentrated virus preparation was used for 
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infection and stored at 4°C for up to one month. For long-term storage, aliquots were 
kept at -80°C. 
 Infection of primary rat cortical neurons was carried out in 24-well plates with 
250,000 cells plated per well in 1 ml medium. At 4 days in vitro (div), 700 µl medium 
was removed and 75 µl concentrated virus was added per well. Cells were incubated 
overnight and the same medium was added back to the cells. Cells were cultured for 
another 6 days before being used in experiments. 
3.3 RNA isolation 
RNA extraction of PC12-G, NG108-15 and primary rat cortical neurons was carried 
out in 6-well plates with the RNeasy Mini Kit (Qiagen) according to the 
manufacturer‟s instructions. The concentration of the RNA was determined by 
spectrophotometry. 
3.4 DNase digestion 
RNA samples were treated with 0.25 U DNase I (Roche) per 1 µg RNA and incubated 
at 37 °C for 20 min. The DNase was inactivated by addition of EDTA (final concen-
tration of 8 mM) and incubation at 75 °C for 10 min. The RNA was stored at -80°C. 
3.5 Reverse transcriptase polymerase chain reaction (RT-PCR) 
3.5.1 Complementary DNA (cDNA) synthesis 
1 µg DNase-digested RNA was reverse-transcribed with the SuperScript II Reverse 
Transcriptase (RT) (Invitrogen). RNA, 50 ng random hexamers and 10 µmol dNTP-
Mix were incubated at 65°C for 5 min in a total volume of 12 µl. The reaction was 
chilled to 8°C and 10 µl RT-Mix was added. The RT-Mix contained 2X RT buffer, 
100 µmol MgCl2, 0.2 µmol DTT, 20 U RNase inhibitor and 50 U RT. The reaction 
was incubated at 25°C for 10 min, 42°C for 50 min and at 70°C for 15 min to heat-
inactivate the RT. As a negative control, the reaction was performed without the 
SuperScript II RT. The cDNA was diluted 1:2 and stored at -20°C. 
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3.5.2 Polymerase chain reaction (PCR) 
2.5 µl cDNA, 1X PCR buffer, 2.5 mM MgCl2, 800 µM dNTP-Mix, 100 nM Primer-
Mix and 0.5 U Taq-Polymerase were diluted in a total volume of 25 µl. The reaction 
was incubated for 5 min at 95°C, followed by 25-35 cycles at 95°C (denaturation), 
55°C (annealing) and 72°C (elongation) for 30 sec, respectively. After a final 
incubation at 72°C for 7 min the reaction was cooled to 4°C and stored at -20°C. As 
negative controls, the reaction was performed with the RT reaction not containing any 
enzyme as well as with water instead of cDNA. 
3.6 Quantitative real time polymerase chain reaction (qRT-PCR) 
2 µl cDNA, 1X iQ SYBR Green Supermix (containing the fluorescent dye SYBR 
Green I) and 200 nM Primer-Mix were diluted in a total volume of 25 µl. The reaction 
was incubated for 3 min at 95°C, for 40 cycles at 95°C for 10 sec (denaturation) and 
55°C for 45 sec (annealing and elongation), and at 95°C and 55°C for 1 min each. 
After real time PCR amplification, a melting curve was performed, for which the 
temperature was raised by 0.5°C from 55°C to 95°C for 10 sec each to ensure 
detection of the desired amplicon. As negative control, the reaction was performed 
with water instead of cDNA. PCR was performed for the gene of interest as well as 
for the housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase). For 
both genes, seven standards were run (2 pg – 0.128 fg; successive 5-fold dilution). 
cDNA levels of the gene of interest were normalized to GAPDH levels. 
3.7 Cloning 
Plasmids were cut with restriction enzymes in their respective buffers. 5-10 µg 
plasmid DNA was digested 2 h to overnight. Fragments were separated on an agarose 
gel and purified with the QIAquick Gel Extraction Kit. To prevent self-ligation, the 
vector DNA was dephosphorylated with calf intestinal alkaline phosphatase (CIP; 0.5 
U/µg DNA) in 1X NEBuffer 3 for 1 h at 37°C. The treated DNA was cleaned up with 
the Wizard DNA clean-up system. Vector and insert DNA were diluted 1:3 in 1X 
DNA dilution buffer (maximal amount of DNA was 200 ng) and ligated with the T4 
DNA ligase in 1X T4 ligation buffer. The reaction was incubated for 5 min at RT and 
transformed into E. coli DH5α competent cells. 40 µl cells were thawed on ice, 2 µl 
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cloning reaction was added and incubated for 5-30 min on ice. Cells were heat-
shocked for 30 sec at 42°C. 250 µl SOC medium (Super Optimal broth medium + 
glucose to initiate Catabolite repression) was added and the cells were incubated for 1 
h at 37°C with shaking. 50-150 µl were spread on an LB plate containing 100 µg/ml 
ampicillin, IPTG and X-Gal and incubated overnight at 37°C. 5-10 white colonies 
were picked and cultured in 4 ml selective LB medium. The plasmid DNA was 
isolated with the QIAprep Spin Miniprep Kit, digested with respective restriction 
enzymes and run on an agarose gel. 100-200 ml selective medium was inoculated 
with a positive clone and plasmid DNA was isolated with the QIAGEN Plasmid Maxi 
Kit. Glycerol stocks (20% glycerol) were made of the bacterial culture and stored at -
80°C. 
 Plasmids were sequenced by the dideoxy chain-termination method (DNA 
Sequencing Facility, NINDS, National Institutes of Health). 
3.8 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate DNA fragments according to their 
size with small fragments running faster than large ones. The concentration of the 
agarose was chosen depending on the size of the DNA fragments. 1.8% agarose was 
used to separate fragments ranging in size from 100-300 bp and 0.8% agarose was 
used for fragments larger than 500 bp. Agarose was dissolved in 1X TAE (Tris-
Acetate-EDTA) buffer by gentle boiling in a microwave and 0.2 µg/ml ethidium 
bromide (EtBr) was added. 1X DNA gel loading solution was added to the DNA and 
loaded onto the gel. The gel was run at 100 V for 1 to 1.5 h. The EtBr stained bands 
were visualized on a UV transilluminator and imaged. 
3.9 Immunoblotting 
NG108-15 and primary rat cortical cells (in 12-well plates) were lysed in 100 µl of 
freshly prepared lysis buffer (1X NuPAGE LDS sample buffer, 1X NuPAGE 
reducing agent, 1X Roche cocktail inhibitor tablet and 1X Halt phosphatase inhibitor 
cocktail) and sonicated for 10 sec to reduce sample viscosity. Samples were heat-
treated for 5 min at 95°C and micro-centrifuged. Standards (See Blue Plus 2 
Prestained Standard and Magic Mark XP Western Standard) and samples were loaded 
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onto a NuPAGE Novex Pre-Cast 4-12% Bis-Tris Gel and run at 120 V for 1.5 h in 1X 
NuPAGE MOPS SDS Running Buffer. Separated proteins were electrotransferred to a 
nitrocellulose membrane (Filter Paper Sandwich, 0.45-µm pore size) at 30 V for 1.5 h 
in cold 1X NuPAGE transfer buffer. The transferred proteins were visualized with 
PonceauS staining. The membrane was blocked with TBST (50 mM Tris-HCl [pH 
8.0], 150 mM NaCl, 0.1% Tween 20) + 5% skim milk for 1 h at room temperature 
before incubation with the primary antibody overnight at 4 °C. The membrane was 
washed three times for 15 min with TBST before incubating with the HRP-conjugated 
secondary antibody for 1 h at room temperature. Following three 15-min washing 
steps in TBST and one in TBS (50 mM Tris-HCl [pH 8.0], 150 mM NaCl), 
immunoreactive bands were visualized with the Super Signal West Pico 
Chemiluminescence Substrate, the FluorChem 8800 Imaging System (Alpha 
Innotech) and iVision software. Exposure times varied from 30 sec to 8 min 
depending on the intensity of the signal. To remove the bound antibody, the 
membrane was incubated in Restore Western Blot Stripping Buffer for 15 min and 
washed twice in TBS. Blocking, antibody incubation and washing was carried out 
under gentle agitation. The membrane was dried and stored at RT. Signals were 
quantified with the ImageJ software. 
3.10 Single cell calcium measurements 
Cells were plated onto 1.5-cm-diameter glass cover slips (in 12-well plates) coated 
with 0.5 mg/ml poly-L-lysine and incubated overnight. Before coating, cover-slips 
were soaked in alcohol for 5 min, washed, soaked in 0.1 M nitric acid for 5 min, 
washed again and air-dried. Cover slips were sterilized at 80°C for at least 30 h. 
Before the experiment, cells were washed once with Krebs-Ringer buffer (KRB: 20 
mM HEPES, 125 mM NaCl, 5.5 mM glucose, 5 mM KCl, 1 mM Na2HPO4, 1 mM 
MgSO4 and 1 mM CaCl2; pH 7.3) and loaded with 4 µM fura-2 AM for 22 min under 
gentle agitation. Cells were washed once with KRB and incubated for an additional 22 
min in KRB. Cover slips were mounted onto a custom-built perfusion chamber and 
placed on an inverted Olympus IX70 microscope. Cells were perfused with KRB in 
the presence or absence of drugs at a flow rate of 800 µl/min. Ca
2+
-free measurements 
were carried out in KRB without CaCl2 supplemented with 100 µM EGTA. 
Intracellular Ca
2+ 
concentrations were measured using the 340/380 excitation ratio (R 
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340/380) and an emission wavelength of 510 nm. Images were captured every 2 sec 
and analyzed with the software MetaFluor. Cells simultaneously expressing the 
protein of interest and the easily detectable tracer GFP from a single bicistronic 
mRNA were selected based on fluorescence detection. 
3.11  [3H]-norepinephrine uptake and release assay 
Catecholamine secretion from dense-core vesicles (DCVs) in intact PC12-G cells was 
assayed by the release of pre-loaded radioactive norepinephrine (NE). Cells were 
plated onto 48-well plates and labeled overnight at 37°C with 1 µCi/ml Levo-7[
3
H]-
Norepinephrine (1 mCi/ml, 12.0 Ci/mmol) in medium containing 0.5 mM ascorbic 
acid. Cells were washed once with medium and incubated in medium in the presence 
or absence of drugs for the indicated time period at 37°C. The supernatant was 
collected and cells were lysed in medium containing 1% Triton-X 100 for 30 min 
under constant agitation. 200 µl of the supernatant and cell lysate, respectively, were 
mixed with 5 ml LSC cocktail and the level of radioactivity was determined by liquid 
scintillation counting. The secreted [
3
H]-NE was calculated as the percentage of the 
total radioactivity. 
3.12 Cyclic AMP measurements 
Intracellular cAMP levels were measured with the cAMP Biotrak 
Enzymeimmunoassay (EIA) System (Amersham Biosciences) using the non-
acetylation EIA procedure with the provided lysis reagent according to the 
manufacturer‟s instructions. Cells were plated onto 48-well plates and incubated 
overnight. Where noted, cells were pre-treated with varying concentrations of the AC-
inhibitor 2ʹ5ʹ-dideoxyadenosine for 30 min. Following pre-treatment, cells were 
stimulated with 100 nM PACAP-38 or 25 µM forskolin in medium containing 500 
µM of the non-selective phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine 
(IBMX) for 20 min at 37°C. 
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3.13 Induction of cell death in primary rat cortical neurons and 
assessment of cell viability 
3.13.1 Induction of cell death by glutamate-induced excitotoxicity 
Excitotoxicity was induced with 5 µM N-methyl-D-aspartic acid (NMDA) or 1 mM 
L-glutamic acid. After incubating the cells for various time periods, viability was 
assessed with the MTT (3.13.3) assay or PI staining (3.13.4). 
3.13.2  Induction of cell death by oxygen-glucose-deprivation (OGD) 
Neurobasal medium was changed to OGD medium (Neurobasal-A medium without 
glucose supplemented with 1X B-27 and 0.5 mM L-glutamine) and the cells were 
placed into a humidified OGD chamber. Cells were flushed for 30 min with 95% N2 
and 5% CO2 (flow rate: 4 L/min) at RT. After flushing, the chamber was sealed and 
incubated for another 2.5 h at 37°C under 95% air and 5% CO2 conditions. The 
medium was replaced with Neurobasal-A medium supplemented with 1X B-27 and 
0.5 mM L-glutamine and after another 21-h-incubation (total incubation of 24 h) cell 
viability was assessed with the MTT assay (3.13.3). 
3.13.3  MTT cell viability assay 
Cell viability of primary rat cortical neurons (in 24-well plates) was determined with 
the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazoliumbromide (MTT) assay. The 
yellow MTT solution is converted to water-insoluble MTT-formazan of blue color by 
mitochondrial dehydrogenases of living cells. MTT was dissolved in PBS at 5 mg/ml 
and filtered to sterilize and remove residual insoluble residues and added to cells (60 
µl per 500 µl medium). Cells were incubated at 37°C for 2 h and the blue crystals 
were solubilized with SDS-DMF solution (20% SDS in 50% DMF, pH 4.7; 0.5 ml per 
0.5 ml medium). After overnight-incubation at 37°C, 200 µl were transferred to a 96-
well plate and read on a microplate reader. The intensity was measured 
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3.13.4 Propidium iodide (PI) staining of dead cells 
Primary rat cortical neurons were incubated with 2 µg/ml propidium iodide (PI) for 10 
min at 37°C. PI intercalates into double-stranded DNA. It can penetrate cell 
membranes from dying or dead cells but is excluded from viable cells. For DNA 
staining of all cells, cultures were incubated with 10 µg/ml Hoechst 33342 20 min 
prior to PI staining. Pictures of the red-fluorescent PI- and the blue-fluorescent 
Hoechst-stained nuclei were taken on a Nikon eclipse Ti inverted microscope using 
NIS Elements software. 
3.14 Statistical analysis 
Statistical analysis was carried out in Prism 4 (GraphPad Software) by unpaired t-test, 
one-way ANOVA with Dunnett‟s or Tukey‟s Multiple Comparison Test or two-way 
ANOVA with Bonferroni post-tests. Significance was set at p < 0.05. 




4.1 Second messenger generation and catecholamine secretion by 
different splice variants of the PAC1 receptor in neuroendocrine and 
neural cells 
To investigate the importance of the different insertions in the third intracellular loop 
(ic3) of PAC1 in PACAPergic neural signaling, the PAC1null, hop1 and hip receptor 
variants with a full-length N-terminus were expressed in pheochromocytoma PC12-G 
and neuroblastoma x glioma NG108-15 cells and intracellular cAMP and calcium 
elevation and catecholamine (CA) secretion were measured. Experiments were 
extended to primary rat cortical neurons. 
4.1.1 Functional characterization of the bovine PAC1hop receptor (bPAC1hop) 
in PC12-G cells 
The bovine PAC1hop1 receptor (bPAC1hop) was stably introduced into the rat 
pheochromocytoma-derived PC12-G cell line as previously described (Mustafa et al., 
2007). Briefly, cells were transfected with pcDNA3 containing bPAC1hop using 
Lipofectamine
 
and selected with G418. A stably transfected clone, expressing 
bPAC1hop at physiological levels found in bovine chromaffin cells (BCCs) was 
chosen (PC12-bPAC1hop).  
Naive PC12-G cells express sufficient levels of PAC1 to provide a maximal 
cAMP response. Levels are too low, however, to drive a full Ca
2+
 response and CA 
secretion (Mustafa et al., 2007). To determine which PACAP receptors are driving a 
full cAMP and a low-level Ca
2+
 response in PC12-G cells, an analysis of VPAC/PAC 
receptor-mRNAs was performed by RT-PCR. Naïve PC12-G cells expressed low 
levels of the PAC1hop and very low levels of the PAC1hip receptor variant, but no 
expression of PAC1null or VPAC1 and 2 receptors was detected (Fig. 6A), suggesting 
that the PACAP-mediated response in PC12-G cells is mediated predominantly by 
PAC1hop with a minor contribution of PAC1hip. 




Figure 6: PC12-G cells express low levels of the PAC1hop and very low levels of the 
PAC1hip receptor variant. (A) RT-PCR analysis of endogenous VPAC1, VPAC2 and PAC1 
receptors in PC12-G cells. Total RNA was reverse-transcribed and PCR-amplified (35 cycles) 
with different primer pairs for VPAC1, VPAC2 and PAC1. To differentiate between PAC1 
splice variants of the third intracellular loop, different primer pairs within the transmembrane 
region 5 and 6 (TM 5 and 6) were used. The same forward primer (F) was used with different 
reverse primers (R): F/R generates a 187- or 271-bp fragment, depending on whether or not a 
hip- or hop-insert is present; the hop-specific primer pair F/hopR generates a 200-bp 
fragment; the hip-specific primer pair F/hipR generates a 142-bp fragment. Primers for 
VPAC1 generate a 107-bp fragment and for VPAC2 a 133-bp fragment. GAPDH product size 
is 168-bp. M: 100-bp DNA ladder. (B) Schematic representation of PAC1 primer pairs. 
4.1.1.1 bPAC1hop increases the intracellular Ca2+ response, which consists of 
Ca
2+ 
mobilization and influx 
The expression of bPAC1hop in PC12-G cells reconstituted a Ca
2+
 response seen in 
primary BCCs as determined by single cell Ca
2+ 
imaging experiments of naïve PC12 
and PC12-bPAC1hop cells, confirming previously published data by T. Mustafa. 
Naive PC12 cells responded to 100 nM PACAP with a very small but prolonged 




]i), whereas PC12-bPAC1hop cells 
showed a large and rapid rise of [Ca
2+
]i followed by a large persisting plateau. 





influx was similar in both cell lines as determined by 
stimulation with 55 mM KCl following stimulation with PACAP (Fig. 7A). To 
differentiate between Ca
2+ 
influx from the extracellular and Ca
2+ 
release from 
intracellular stores (i.e., Ca
2+
 mobilization), cells were stimulated with PACAP in 
Ca
2+
-free buffer. Both PC12 and PC12-bPAC1hop cells showed an initial Ca
2+
 
mobilization, which was followed by a prolonged influx upon reintroduction of Ca
2+
. 
Mobilization and influx were much greater in bPAC1hop-expressing cells, reflecting 
the limited coupling to Ca
2+
 of endogenous PAC1 receptors expressed in naïve PC12-
G cells (Fig. 7B). 
 
Figure 7: Expression of the bovine PAC1hop receptor (bPAC1hop) in PC12-G cells 
increases intracellular Ca
2+
 mobilization and influx upon PACAP treatment. PC12 cells 
(black line) and PC12-bPAC1hop cells (gray line) were loaded with 4 µM fura-2 AM and 
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stimulated with 100 nM PACAP-38 for 75 sec in Ca
2+
-containing (A) or Ca
2+
-free KRB (B). 
Insert in (A) shows depolarization-induced Ca
2+
 influx by 55 mM KCl following PACAP 
treatment. Intracellular Ca
2+
 concentrations were measured in single cells using the 340/380 
excitation ratio (R 340/380) and an emission wavelength of 510 nm. Images were captured 
every 2 sec. Plots represent the average ± SEM of at least three independent experiments. 
Each experiment represents 20-50 cells (A: PC12: n=111, PC12-bPAC1hop: n=99; B: PC12: 
n=106, PC12-bPAC1hop: n=189). 
4.1.1.2 bPAC1hop increases acute and confers prolonged catecholamine 
secretion 
To determine whether the increased Ca
2+
 response of PC12-bPAC1hop cells is 
reflected in the secretory response, the release of catecholamines (CAs) was measured 
in PC12 and PC12-bPAC1hop cells upon treatment with 100 nM PACAP. PC12-G 
cells released low levels of pre-loaded [
3
H]-norepinephrine (NE) after a 30-min-
exposure to PACAP, which is in disagreement with previously published data by 
Mustafa et al., demonstrating a lack of CA release in naïve PC12-G cells. 
Experiments by Mustafa et al. were carried out in Krebs-Ringer buffer (KRB) and 
showed a high basal release (approximately 10% of total content). In this study, 
complete medium was used, which reduced basal release to about 5%, unmasking 
PACAP-mediated release. CA release was significantly enhanced in PC12-bPAC1hop 
cells to about 30% of total content, which is comparable to the release measured by 
Mustafa et al. and similar to membrane depolarization-mediated release by 55 mM 
KCl. KCl-mediated release was slightly higher in PC12-bPAC1hop cells compared to 
naïve PC12-G cells (~25% of total content), suggesting a larger readily releasable 
pool (RRP) size of DCVs in these cells (Fig. 8). 
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Figure 8: Expression of the bovine PAC1hop receptor (bPAC1hop) enhances 
catecholamine secretion in PC12-G cells. PC12 cells (black bars) and PC12-bPAC1hop 
cells (white bars) were labeled with 1 µCi/ml Levo-7[
3
H]-Norepinephrine and stimulated with 
100 nM PACAP-38 or 55 mM KCl for 30 min. The supernatant was collected, cells were lysed 
and the level of radioactivity was determined. The secreted [
3
H]-NE in the supernatant was 
calculated as the percentage of total radioactivity. Values represent the grand mean ± SEM of 
at least four independent experiments performed in duplicates. *** P < 0.001 versus control or 
between treatments; one-way ANOVA, with Tukey’s Multiple Comparison Test. ### P < 0.001 
between cell lines; two-way ANOVA, with Bonferroni post-tests.  
To differentiate between acute and sustained secretion, CA release was 
measured after different incubation times. Both PC12 and PC12-bPAC1hop cells 
responded to 100 nM PACAP with an acute release of pre-loaded [
3
H]-NE within 5 
min. Acute secretion was higher in PC12-bPAC1hop cells. Moreover, expression of 
the bPAC1hop receptor conferred sustained secretion (5-60 min), which was not seen 
in naïve PC12-G cells, suggesting that the low density of endogenous PAC1 receptors 
in PC12-G cells is not sufficient to drive a full acute secretory response and more 
importantly a prolonged secretory response (Fig. 9A). Membrane depolarization with 
55 mM KCl induced acute but not prolonged CA secretion, which was also increased 
in PC12-bPAC1hop cells (Fig. 9B), in agreement with an increased KCl-mediated 








Figure 9: Expression of the bovine PAC1hop receptor (bPAC1hop) in PC12-G cells 
confers prolonged PACAP-evoked catecholamine secretion. Cells were labeled with 1 
µCi/ml Levo-7[
3
H]-Norepinephrine and stimulated with (A) 100 nM PACAP-38 for 5, 30, 60 or 
90 min or (B) 55 mM KCl for 5 or 30 min. The supernatant was collected, cells were lysed and 
the level of radioactivity was determined. The secreted [
3
H]-NE in the supernatant was 
calculated as the percentage of total radioactivity and is shown as % release/min. Basal 
release was subtracted from the respective time interval (see Table 1 for basal versus 
PACAP-stimulated release). Values represent the grand mean ± SEM of three to six 
independent experiments performed in duplicates. *** P < 0.001 versus PC12 cells; two-way 
ANOVA, with Bonferroni post-tests. 
Time interval [min] 0-5 5-30 30-60 60-90 
PC12 basal 0.42 ± 0.07 0.09 ± 0.02 0.06 ± 0.02 0.11 ± 0.02 
PACAP  1.11 ± 0.07 0.20 ± 0.01 0.14 ± 0.05 0.27 ± 0.11 
PC12-
bPAC1hop 
basal 0.62 ± 0.09 0.11 ± 0.02 0.12 ± 0.01 0.14 ± 0.04 
PACAP  2.20 ± 0.12 0.83 ± 0.06 0.77 ± 0.06 0.58 ± 0.01 
Table 1: Basal versus PACAP-stimulated CA release in % release / min in PC12 and 
PC12-bPAC1hop cells. Values represent the grand mean ± SEM of experiments shown in 
Figure 9A.  
4.1.2 Functional characterization of the rat PAC1hop, null and hip receptor 
variants (rPAC1hop, null and hip) in PC12-G cells 
The rat PAC1hop1, null and hip receptor variants were stably introduced into PC12-G 
cells through infection with gammaretroviral particles to characterize and compare the 
B 
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three different PAC1 variants. Moreover, the expression of rat receptors in a cell line 
derived from a rat tumor abolishes inter-species differences that were present in the 
PC12-bPAC1hop cell line. The rat PAC1 receptors were expressed from a CMV 
promoter generating stable cell lines with similar expression levels. Viral particles 
were made with the bicistronic retroviral vector pPRIG and the expression of the 
receptor was monitored by the expression of enhanced green fluorescent protein 
(eGFP) from its IRES-dependent cistron. The transfection efficiency was between 45 
and 80%. Specifically, 58% of pPRIG-rPAC1hop, 79% of pPRIG-rPAC1null, 45% of 
pPRIG-rPAC1hip and 56% of pPRIG-control infected PC12 cells were GFP-positive. 
Figure 10 shows representative pictures of PC12 cells over-expressing the rat 
PAC1hop receptor (PC12-rPAC1hop). 
 
 
Figure 10: Photomicrographs of PC12 cells stably expressing rat PAC1hop-IRES-eGFP 
(PC12-rPAC1hop). Cells were infected with viral particles made with the bicistronic retroviral 
vector pPRIG. PC: phase contrast, GFP: green fluorescent protein (grayscale image). 
4.1.2.1 rPAC1hop and null increase the intracellular Ca2+ response 
Expression of rPAC1hop in PC12-G cells increased the intracellular Ca
2+
 response 
upon treatment with 100 nM PACAP, reminiscent of the Ca
2+
 response seen in PC12 
cells expressing the bovine PAC1hop receptor as shown in Figure 7A. The initial rise 
in [Ca
2+
]i, which was attributable to Ca
2+ 
release from intracellular stores was slightly 
higher in bPAC1hop- compared to rPAC1hop-expressing cells, whereas the prolonged 
Ca
2+ 
influx plateau phase was similar in the bovine and rat receptor-expressing cell 
lines. Expression of rPAC1null also increased the intracellular Ca
2+
 response similar 
to rPAC1hop, but with a slightly smaller initial rise, suggesting that the hop cassette is 
not required for mediating an intracellular Ca
2+
 response. Expression of rPAC1hip, in 
contrast, did not elevate the intracellular Ca
2+
 response beyond the small rise observed 
in naïve PC12-G cells, suggesting that the hip cassette abolishes coupling to Ca
2+
. 
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Expression of GFP alone did not affect the elevation of [Ca
2+
]i elicited by PACAP, 





similar in the five cell lines as determined by stimulation with 55 mM KCl following 
stimulation with PACAP (Fig. 11). 
 
Figure 11: Expression of the rat PAC1hop and null but not the hip receptor in PC12-G 
cells increases the PACAP-induced Ca
2+ 
response. Cells were loaded with 4 µM fura-2 AM 
and stimulated with 100 nM PACAP-38 for 75 sec in KRB. Insert shows depolarization-
induced Ca
2+
 influx by 55 mM KCl following PACAP treatment. [Ca
2+
]i were measured in 
single cells using the 340/380 excitation ratio (R 340/380) and an emission wavelength of 510 
nm. Images were captured every 2 sec. Plots represent the average ± SEM of five (naïve), 
seven (GFP and hip) or eight (null and hop) independent experiments. Each experiment 
represents 10-50 cells (hop: n=236, null: n=269, hip: n=172, GFP: n=217, naïve: 167). 
4.1.2.2 rPAC1hop and null increase acute catecholamine secretion but only 
rPAChop confers prolonged secretion 
Next, the effect of the different rat PAC1 receptor variants on CA secretion was 
examined in PC12-G cells. Expression of rPAC1hop and null increased PACAP-
induced acute release of pre-loaded [
3
H]-NE within 5 min, whereas only rPAC1hop 
conferred sustained secretion (5-60 min), suggesting that PACAP-mediated long-term 
release of CAs requires the presence of the hop cassette in the third intracellular loop 
of the receptor. Expression of rPAC1hip did not increase the secretory response 
beyond the low-level acute release observed in naïve PC12 cells, in agreement with a 
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lack of coupling to Ca
2+
. Expression of GFP alone did not affect the secretory 
behavior (Fig. 12). 
 
Figure 12: Expression of the rat PAC1hop and null receptor in PC12-G cells increases 
acute PACAP-evoked catecholamine secretion, but only PAC1hop confers prolonged 
secretion. Expression of PAC1hip is without effect. Cells were labeled with 1 µCi/ml Levo-
7[
3
H]-Norepinephrine and stimulated with 100 nM PACAP-38 for 5, 60 or 90 min. The 
supernatant was collected, cells were lysed and the level of radioactivity was determined. The 
secreted [
3
H]-NE in the supernatant was calculated as the percentage of total radioactivity 
and is shown as % release/min. Basal release was subtracted from the respective time 
interval (see Table 2 for basal versus PACAP-stimulated release). Values represent the grand 
mean ± SEM of three to six independent experiments performed in duplicates. . *** P < 0.001, 
** P < 0.01 versus naïve PC12 cells; two-way ANOVA, with Bonferroni post-tests. 
Time interval [min] 0-5 5-60 60-90 
Naïve 
PC12 
basal 0.49 ± 0.10 0.07 ± 0.01 0.11 ± 0.02 
PACAP 1.13 ± 0.10 0.14 ± 0.03 0.27 ± 0.11 
PC12-
GFP 
basal 0.52 ± 0.06 0.09 ± 0.01 0.09 ± 0.00 
PACAP 1.32 ± 0.26 0.28 ± 0.02 0.21 ± 0.07 
PC12-
rPAC1hop 
basal 0.69 ± 0.10 0.08 ± 0.01 0.07 ± 0.02 
PACAP 1.73 ± 0.13 0.55 ± 0.05 0.43 ± 0.04 
PC12-
rPAC1null 
basal 0.64 ± 0.05 0.07 ± 0.01 0.07 ± 0.01 
PACAP 1.72 ± 0.16 0.41 ± 0.04 0.36 ± 0.05 
PC12-
rPAC1hip 
basal 0.53 ± 0.02 0.07 ± 0.01 0.07 ± 0.02 
PACAP 1.17 ± 0.05 0.26 ± 0.04 0.31 ± 0.02 
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Table 2: Basal versus PACAP-stimulated CA release in % release / min in naïve PC12, 
PC12-GFP and PC12-rPAC1hop, null and hip cells. Values represent the grand mean ± 
SEM of experiments shown in Figure 12.  
4.1.3 Functional characterization of rPAC1hop, null and hip in NG108-15 cells 
To characterize each individual PAC1 splice variant separately in neural cells, the 
mouse neuroblastoma x rat glioma cell line NG108-15 was transduced with the rat 
PAC1null, hop1 or hip receptor variants. NG108-15 cells expressed negligible levels 
of PACAP receptors endogenously. A very low expression of VPAC2 and PAC1hop 
receptors was observed (Fig. 13A). Levels were too low, however, to evoke a 
response upon PACAP treatment. NG108-15 cells are capable of G protein signaling 
through activation of endogenous GPCRs for other neuropeptide ligands (Ghadessy 
and Kelly, 2002; Hamprecht et al., 1985; Ishihara et al., 1991; Propst et al., 1979) 
without having any “background” PACAP response as observed in PC12-G cells and 
were therefore chosen to characterize PAC1 splice variant-specific signaling. NG108-
15 cells stably over-expressing the rat PAC1 receptor splice variants hop1, null and 
hip, respectively, were generated through infection with gammaretroviral particles as 
described for PC12-G cells (4.1.2). The transfection efficiency was between 75 and 
90%. Specifically, 89% of pPRIG-rPAC1hop, 81% of pPRIG-rPAC1null, 76% of 
pPRIG-rPAC1hip and 86% of pPRIG-control infected NG108-15 cells were GFP-
positive. Fig. 13B and C show RT-PCR analysis of reverse-transcribed mRNAs from 
the NG108-15 cell lines PAC1null, PAC1hop and PAC1hip and representative 
pictures of NG108-15-rPAC1hop cells. 
 
 




Figure 13: Expression of rat PAC1 receptor variants in NG108-15 cells before and after 
retroviral transduction. RT-PCR analysis of (A) endogenous VPAC1, VPAC2 and PAC1 
receptors in NG108-15 cells and (B) PAC1 receptors in cells that were infected with viral 
particles made with the bicistronic retroviral vector pPRIG to generate stably expressing cell 
lines (PAC1null, PAC1hop and PAC1hip). Total RNA was reverse-transcribed and PCR-
amplified (35 cycles) using different primers within the transmembrane region 5 and 6 (TM 5 
and 6). The same forward primer (F) was used with different reverse primers (R): F/R 
generates a 187- or 271-bp fragment, depending on whether or not a hip- or hop-insert is 
present; the hop-specific primer pair F/hopR generates a 200-bp fragment; the hip-specific 
primer pair F/hipR generates a 142-bp fragment (schematic representation see Fig. 6B). 
Primers for VPAC1 generate a 107-bp fragment and for VPAC2 a 133-bp fragment. GAPDH 
product size is 168-bp. M: 100-bp DNA ladder. (C) Photomicrographs of NG108-15 cells 
stably expressing rat PAC1hop-IRES-eGFP (NG108-15-rPAC1hop). PC: phase contrast, 
GFP: green fluorescent protein. 
4.1.3.1 rPAC1hop, null and hip confer intracellular cAMP generation 
PAC1 receptors potently stimulate adenylate cyclases (ACs) to increase intracellular 
cAMP levels. Expression of all three rat PAC1 receptor splice variants hop, null and 
hip in NG108-15 cells conferred an increase in intracellular cAMP generation upon 
treatment with 100 nM PACAP, indicating that coupling to ACs, presumably through 
Gs, was reconstituted in these cells. Cyclic AMP production was greater in PAC1hop- 
and null- compared to hip-expressing cells, which is in agreement with the first report 
  Results 
49 
 
published on the differential signaling properties of the different rat PAC1 splice 
variants in non-neural cells (Spengler et al., 1993). The expression of GFP alone was 
without effect. The amount of cAMP generated upon stimulation with 25 µM of the 
AC activator forskolin was, as expected, similar in all cell lines and represents the 
maximal amount of intracellular cAMP generation. PACAP-induced cAMP 
generation was calculated as the percentage of maximal cAMP generation (Fig. 14). 
The absolute amounts of cAMP in untreated cells as well as those generated upon 
PACAP or forskolin treatment are shown in Table 3.  
 
Figure 14: Expression of the rat PAC1 receptor splice variants hop, null and hip in 
NG108-15 cells confers intracellular cAMP production upon PACAP treatment. Cyclic 
AMP generation is greater in PAC1hop- and null- than in PAC1hip-expressing cells. 
Cells were treated with 100 nM PACAP-38 for 20 min and intracellular cAMP levels were 
measured. Plot represents the grand mean ± SEM of three independent experiments 
performed in triplicates. Values are expressed as percentage of maximal intracellular cAMP 
generation, which was determined by stimulation with 25 µM forskolin. *** P < 0.001, ** P < 
0.01, * P < 0.05 versus GFP- and between PAC1 variant-expressing cell lines; one-way 
ANOVA, with Tukey’s Multiple Comparison Test. 
 GFP  PAC1hop  PAC1null  PAC1hip  
control  0.11 ± 0.02  0.15 ± 0.03  0.13 ± 0.004  0.11 ± 0.02  
PACAP  0.17 ± 0.04  4.60 ± 1.07  4.99 ± 1.30  1.86 ± 0.34  
Forskolin  13.72 ± 4.83  15.14 ± 2.07  15.52 ± 4.04  15.19 ± 5.29  
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Table 3: Absolute values of intracellular cAMP levels in pmol/well in NG108-15 cells 
expressing the rat PAC1 receptor splice variants or GFP. Values represent the grand 
mean ± SEM of the three experiments shown in Figure 14. 
 To test whether intracellular cAMP generation can be blocked 
pharmacologically, NG108-15-rPAC1hop cells were incubated with various 
concentrations of the AC inhibitor 2ʹ5ʹ-dideoxyadenosine (ddAd) (Tesmer et al., 
2000) prior to PACAP treatment. ddAd reduced PACAP-induced intracellular cAMP 
generation in a concentration-dependent manner. However, even the highest 
concentration of ddAd used did not block cAMP generation by PACAP completely 
(control and 600 μM ddAd + PACAP: P < 0.001 in unpaired t-test). The amount of 
cAMP generated upon PACAP treatment with or without pre-treatment with ddAd 
was calculated as the percentage of cAMP generated upon treatment with 25 µM 
forskolin which represents the maximal amount of intracellular cAMP generation 
(Fig. 15). The absolute amounts of cAMP in untreated and treated cells are shown in 
Table 4. 
 
Figure 15: The AC inhibitor 2ʹ5ʹ-dideoxyadenosine reduces PACAP-induced 
intracellular cAMP generation in a concentration-dependent manner in NG108-15-
rPAC1hop cells. Cells were pre-treated for 30 min with 150, 300 or 600 µM 2ʹ5ʹ-
dideoxyadenosine (ddAd) before treatment with 100 nM PACAP-38 for 20 min and 
measurement of intracellular cAMP levels. Plot represents the grand mean ± SEM of three 
independent experiments performed in triplicates. Values are expressed as percentage of 
maximal intracellular cAMP generation, which was determined by stimulation with 25 µM 
forskolin. ** P < 0.01, * P < 0.05 versus control; one-way ANOVA, with Dunnett’s Multiple 
Comparison Test. 
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control PACAP 150 µM ddAd 
+ PACAP 
300 µM ddAd 
+ PACAP 
600 µM ddAd 
+ PACAP 
Forskolin 
0.13 ± 0.01 5.71 ± 1.56 2.00 ± 0.43 1.47 ± 0.26 1.05 ± 0.18 19.89 ± 3.65 
Table 4: Absolute values of intracellular cAMP levels in pmol/well in NG108-15-
rPAC1hop cells with or without 2ʹ5ʹ-dideoxyadenosine (ddAd) pre-treatment. Values 
represent the grand mean ± SEM of the three experiments shown in Figure 15. 
4.1.3.2 rPAC1hop and null confer an intracellular Ca2+ response 





]i) upon treatment with 100 nM PACAP, whereas 
expression of rPAC1hip was without effect. In both cell lines the response consisted 
of a rapid and transient rise of [Ca
2+
]i reminiscent of IP3 receptor-mediated Ca
2+ 
release from intracellular stores, with no obvious Ca
2+
 influx “plateau phase” as 
observed in PC12-G cells. [Ca
2+
]i elevation was greater in PAC1hop- than in 
PAC1null-expressing cells, suggesting that the efficacy of coupling to Ca
2+ 
is 
increased by expression of the hop cassette in the third intracellular loop of the 
receptor, whereas coupling to  Ca
2+ 
is abolished by expression of the hip cassette. 
Expression of GFP alone was without effect. Depolarization-induced Ca
2+ 
influx was 
similar in the five cell lines as determined by stimulation with 55 mM KCl following 
stimulation with PACAP (Fig. 16). 
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Figure 16: Expression of the rat PAC1hop and null but not the hip receptor in NG108-15 
cells confers an increase in intracellular Ca
2+
 upon PACAP treatment. PAC1hop is more 
efficacious in increasing [Ca
2+
]i than PAC1null. Cells were loaded with 4 µM fura-2 AM 
and stimulated with 100 nM PACAP-38 for 75 sec in KRB. Insert shows depolarization-
induced Ca
2+
 influx by 55 mM KCl following PACAP treatment. Intracellular Ca
2+
 
concentrations were measured in single cells using the 340/380 excitation ratio (R 340/380) 
and an emission wavelength of 510 nm. Images were captured every 2 sec. Plots represent 
the average ± SEM of five (naïve), six (rPAC1hip and GFP) or 19 (rPAC1hop and null) 
independent experiments. Each experiment represents 10-25 cells (hop: n=376, null: n=302, 
hip: n=85, GFP: n=94, naïve: n=94).  
4.1.4 Functional characterization of PACAP-mediated signaling in cultured rat 
cortical neurons 
4.1.4.1 Rat cortical neurons mainly express PAC1hop and null 
PACAP signaling was next examined in primary cultures of rat cortical neurons. To 
determine which PACAP receptors are responsible for mediating PACAP‟s effects, an 
analysis of VPAC/PAC receptor-mRNAs was performed by RT-PCR. Cortical 
neurons predominantly expressed the PAC1hop and null receptor variants. A low 
expression of PAC1hip receptors and a very low expression of VPAC1 and VPAC2 
receptors was also detected, suggesting that PACAP‟s action in primary cortical 
neurons is mainly mediated by the PAC1hop and null receptor variants with a minor 
contribution of PAC1hip and VPACs (Fig. 17). 
 
Figure 17: Rat cortical neurons predominantly express the PAC1null and hop receptor 
variants. (A) RT-PCR analysis of endogenous VPAC1, VPAC2 and PAC1 receptors in 
primary cultures of rat cortical neurons. Total RNA was reverse-transcribed and PCR-
amplified (35 cycles) with different primer pairs for rat VPAC1, VPAC2 and PAC1. To 
differentiate between PAC1 splice variants of the third intracellular loop different primer pairs 
within the transmembrane region 5 and 6 (TM 5 and 6) were used. The same forward primer 
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(F) was used with different reverse primers (R): F/R generates a 187- or 271-bp fragment, 
depending on whether or not a hip- or hop-insert is present; the hop-specific primer pair 
F/hopR generates a 200-bp fragment; the hip-specific primer pair F/hipR generates a 142-bp 
fragment (schematic representation see Fig. 6B). Primers for VPAC1 generate a 107-bp 
fragment and for VPAC2 a 133-bp fragment. GAPDH product size is 168-bp. M: 100-bp DNA 
ladder. (B) Photomicrograph of rat cortical neurons. 
4.1.4.2 PACAP increases intracellular cAMP generation, which can be 
pharmacologically blocked by 2ʹ5ʹ-dideoxyadenosine 
Treatment of rat cortical neurons with 100 nM PACAP resulted in a robust increase of 
intracellular cAMP. The amount generated was approximately 60% of the amount 
generated by supramaximal stimulation of adenylate cyclases (ACs) with 25 μM 
forskolin. The AC inhibitor 2ʹ5ʹ-dideoxyadenosine (ddAd) reduced PACAP-
stimulated cAMP levels in a concentration-dependent manner. At a concentration of 
600 µM, ddAd completely blocked cAMP production. Cyclic AMP generation by 
PACAP with or without ddAd pre-treatment is shown as percentage of maximal 
cAMP generation determined by stimulation with 25 µM forskolin (Fig. 18). The 
absolute amounts of cAMP in untreated and treated cells are shown in Table 5. 
 
Figure 18: PACAP stimulation triggers intracellular cAMP generation in rat cortical 
neurons, which can be blocked by high concentrations of the AC inhibitor 2ʹ5ʹ-
dideoxyadenosine. Cells were treated with 100 nM PACAP-38 for 20 min with or without 
pre-treatment with 150, 300 or 600 µM 2ʹ5ʹ-dideoxyadenosine (ddAd) and intracellular cAMP 
levels were measured. Plot represents the grand mean ± SEM of three independent 
experiments performed in triplicates. Values are expressed as percentage of maximal 
intracellular cAMP generation, which was determined by stimulation with 25 µM forskolin. ** P 
< 0.01, * P < 0.05 versus control; one-way ANOVA, with Dunnett’s Multiple Comparison Test. 
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control  PACAP  150 µM ddAd 
+ PACAP 
300 µM ddAd 
+ PACAP  
600 µM ddAd 
+ PACAP  
Forskolin  
0.12 ± 0.04  1.15 ± 0.41  0.54 ± 0.28  0.43 ± 0.17  0.26 ± 0.10  2.02 ± 0.73  
Table 5: Absolute values of intracellular cAMP levels in pmol/well in rat cortical 
neurons with or without 2ʹ5ʹ-dideoxyadenosine (ddAd) pre-treatment. Values represent 
the grand mean ± SEM of the three experiments shown in Figure 18. 
4.1.4.3 PACAP induces Ca2+ mobilization and influx 
Exposure of rat cortical neurons to 100 nM PACAP also resulted in a rapid elevation 
of [Ca
2+
]i followed by a persisting plateau. To differentiate between Ca
2+ 
mobilization 
and influx, cells were stimulated in Ca
2+
-free buffer. PACAP induced a rapid and 











 entered the 
cell leading to prolonged Ca
2+ 
influx (Fig. 19). The PACAP-induced Ca
2+ 
response 
was reminiscent of the Ca
2+ 
response observed in PAC1hop- or null-over-expressing 
PC12-G cells, which is in agreement with a predominant expression of PAC1hop and 
null receptors in cortical neurons. Approximately 25% of all cells showed no response 
or a very weak response to PACAP. These PACAP-non-responders were excluded 
from Figure 19. KCl stimulation following PACAP treatment induced Ca
2+
 influx in 
only 15% of PACAP-responding cells (left insert in Fig. 19); these cells did not show 
a prolonged Ca
2+
 influx plateau phase upon PACAP treatment. In the majority of 
PACAP-responders, where PACAP elicited both Ca
2+ 
mobilization and influx, KCl 
did not increase intracellular Ca
2+
 levels and instead lead to a slight decrease (right 
insert in Fig. 19; PACAP response shown in Fig. 19 includes KCl-responders and -
non-responders). When cells were stimulated with KCl without previous PACAP 
stimulation, all cells showed a depolarization-induced Ca
2+
 influx (not shown), 
suggesting that PACAP receptor activation modulates voltage-gated calcium channels 
(VGCCs). Moreover, all PACAP-non-responders showed a robust rise in [Ca
2+
]i upon 
depolarization (not shown). 




Figure 19: PACAP stimulation triggers intracellular Ca
2+
 mobilization and influx in the 
majority of rat cortical neurons. Cells were loaded with 4 µM fura-2 AM and stimulated with 
100 nM PACAP-38 for 75 sec in Ca
2+
-containing (black line) or Ca
2+
-free KRB (gray line). 
Inserts show depolarization-induced Ca
2+
 influx by 55 mM KCl following PACAP treatment in 
Ca
2+
-containing buffer. Intracellular Ca
2+
 concentrations were measured in single cells using 
the 340/380 excitation ratio (R 340/380) and an emission wavelength of 510 nm. Images were 
captured every 2 sec. ~75% of all cells respond to PACAP with a robust increase in [Ca
2+
]i, 
whereas the remaining 25% show no or a very weak response and are excluded from this 
graph. ~15% of PACAP-responding cells show a depolarization-induced Ca
2+
 influx following 
PACAP treatment (left insert), whereas 85% do not (right insert). Plots represent the average 
± SEM of four (- Ca
2+
) or 11 (+ Ca
2+
) independent experiments. Each experiment represents 
6-22 cells (- Ca
2+
: n=59, + Ca
2+
: n=155). 
4.2 Signaling to MAPK activation in neural cells 
4.2.1 PACAP activates the MAPK ERK1/2 through cAMP but not PKA in 
NG108-15-rPAC1hop cells 
The importance of the mitogen-activated protein kinase (MAPK) extracellular signal-
regulated kinase (ERK) pathway in mediating PACAP‟s neurotrophic effects has been 
extensively studied in PC12 cells. Here, the activation of ERK was characterized in 
NG108-15 cells. Exposure of NG108-15 cells stably expressing the rat PAC1hop 
receptor to 100 nM PACAP resulted in a rapid activation of ERK as determined by 
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the phosphorylation of the p44/42 MAPK (ERK1/2). The activation was transient 
with its maximum at 2 min and subsiding by 5 min (Fig. 20A+E). The AC activator 
forskolin failed to activate ERK (Fig. 20C). However, PACAP‟s stimulatory effects 
on ERK were blocked by the AC inhibitor 2ʹ5ʹ-dideoxyadenosine (ddAd), suggesting 
that cAMP generation by PACAP is necessary but not sufficient to activate ERK in 
NG108-15 cells. Moreover, the PKA inhibitor H89 did not block ERK activation, 
suggesting a cAMP dependent but PKA independent activation of ERK by PACAP. 
The MEK1/2 inhibitor U0126 completely blocked ERK activation, as expected (Fig. 
20B+F). No treatment affected total ERK levels. PACAP did not activate ERK in 
NG108-15 cells expressing GFP only (Fig. 20D).  
 
 




Figure 20: PACAP rapidly activates ERK1/2 (p44/42 MAPK) in NG108-15-rPAC1hop 
cells. Activation is blocked by the AC inhibitor 2ʹ5ʹ-dideoxyadenosine but not blocked 
by the PKA inhibitor H89. NG108-15-rPAC1hop cells (A-C) and NG108-15-GFP cells (D) 
were stimulated with 100 nM PACAP-38 or 25 µM forskolin in the presence or absence of the 
AC inhibitor 2ʹ5ʹ-dideoxyadenosine (ddAd, 300 µM), the PKA inhibitor H89 (10 µM) or the 
MEK1/2 inhibitor U0126 (10 µM) (30 min pre-treatment with inhibitors). Whole cell extracts 
were harvested after 2 or 5 min. Expression of the rat PAC1hop receptor in NG108-15 cells 
confers a rapid and transient activation of ERK1/2 (A), which is not seen in control cells 
expressing GFP only (D). ERK1/2 activation is unaffected by H89, but blocked by ddAd and 
U0126 (B). Forskolin fails to activate ERK1/2 (C). No treatment affects total ERK1/2 levels. M: 
40 and 50 kDa band. (E+F) Quantification of A and B. Values are expressed as the ratio of 
phospho-ERK divided by total ERK and represent the mean ± SEM of three independent 
experiments performed in singlicates. The control value represents the mean of the fold of 
average control, which was determined by calculating the p-ERK/ERK mean of the three 
control values and dividing each p-ERK/ERK control value by this mean. U0126 is not shown 
in the plot. ** P < 0.01, * P < 0.05 versus control; one-way ANOVA, with Dunnett’s Multiple 
Comparison Test. 
4.2.2 PACAP and forskolin activate the MAPK ERK1/2 through cAMP but not 
PKA in cultured rat cortical neurons 
Primary cultures of rat cortical neurons responded to 100 nM PACAP and 25 μM of 
the AC activator forskolin with a rapid and prolonged activation of the MAPK 
ERK1/2 (p44/42 MAPK) as determined by phosphorylation of the two proteins (Fig. 
21A+D). ERK1/2 activation was blocked by 600 µM of the AC inhibitor 2ʹ5ʹ-
dideoxyadenosine (ddAd). 300 µM ddAd, however, failed to block PACAP-mediated 
ERK activation, indicating that very low levels of cAMP are sufficient to activate 
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ERK (see Fig. 18 for effects of ddAd on PACAP-stimulated cAMP generation). The 
PKA inhibitor H89 failed to block PACAP- as well as forskolin-induced ERK 
activation, suggesting that ERK activation proceeds through cAMP but not PKA in 
cortical neurons. The MEK1/2 inhibitor U0126 completely blocked ERK activation, 













Figure 21: PACAP and forskolin activation of the p44/42 MAPK (ERK1/2) is rapid and 
prolonged in rat cortical neurons (A). Activation is blocked by the AC inhibitor 2ʹ5ʹ-
dideoxyadenosine but not blocked by the PKA inhibitor H89 (B+C). Cells were stimulated 
with 100 nM PACAP-38 or 25 µM forskolin in the presence or absence of the AC inhibitor 2ʹ5ʹ-
dideoxyadenosine (ddAd, 300 and 600 µM), the PKA inhibitor H89 (10 µM) or the MEK1/2 
inhibitor U0126 (10 µM) (30 min pre-treatment with inhibitors). Whole cell extracts were 
harvested after 5 min, 30 min, 1, 3 or 6 h (A) or after 5 min (B+C). ERK activation by PACAP 
and forskolin is rapid and prolonged (A) and unaffected by H89, but blocked by 600 µM ddAd 
and U0126 (B+C). No treatment affects total ERK1/2 levels. M: 40 and 50 kDa band. (D-F) 
Quantification of A-C. Values are expressed as the ratio of phospho-ERK divided by total 
ERK and represent the mean ± SEM of three to seven independent experiments performed in 
singlicates. The control value represents the mean of the fold of average control, which was 
determined by calculating the p-ERK/ERK mean of the control values and dividing each p-
ERK/ERK control value by this mean. U0126 is not shown in the plot. ** P < 0.01, * P < 0.05 
versus control; one-way ANOVA, with Dunnett’s Multiple Comparison Test. 
4.3 Signaling pathways mediating gene induction in neural cells 
4.3.1 PACAP induces STC1 through ERK1/2 but not PKA in NG108-15-
rPAC1hop cells 
In a microarray analysis we identified stanniocalcin 1 (STC1) up-regulated upon 6 h 
of PACAP treatment in PC12-G cells expressing physiological levels of the bovine 
PAC1hop receptor (PC12-bPAC1hop) and in primary bovine chromaffin cells (BCCs) 
(Ait-Ali et al., 2010). In this study the induction of STC1 was examined in cells of the 
central nervous system, where STC1 could be a mediator of PACAP‟s 
neuroprotective effects in e.g., stroke. NG108-15 cells stably over-expressing the rat 
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PAC1hop receptor (NG108-15-rPAC1hop) responded to 100 nM PACAP with an 
induction of STC1 mRNA after 3 and 6 h (Fig. 22A), which was not seen in control 
cells expressing GFP only (Fig. 22B) as measured by qRT-PCR. PACAP-mediated 
STC1 induction after 6 h was completely blocked by the MEK1/2 inhibitor U0126, 
whereas the PKA inhibitor H89 was without effect (Fig. 22C), suggesting that 
PACAP signaling to the STC1 gene proceeds through the MAPK ERK1/2 
independently of PKA activation, which is in agreement with a PKA independent but 
cAMP dependent activation of ERK itself (see Fig. 20). The AC activator forskolin, in 
contrast, induced STC1 mRNA in an H89 sensitive manner (Fig. 22D). Treatment 
with inhibitors only was without effect. These results suggest that two pathways for 
STC1 gene induction co-exist in NG108-15 cells, one through PACAP, where cAMP 
is necessary but not sufficient to activate ERK1/2 independently of PKA and another 
through intracellular cAMP generation only (by forskolin) and activation of PKA. 
 
 




Figure 22: PACAP induces STC1 mRNA after 3 and 6 h in NG108-15-rPAC1hop cells 
(A). Induction after 6 h is blocked by the MEK1/2 inhibitor U0126 but not blocked by the 
PKA inhibitor H89 (C). STC1 induction by forskolin, in contrast, is blocked by H89 (D). 
NG108-15-rPAC1hop cells (A, C, D) and NG108-15-GFP cells (B) were stimulated with 100 
nM PACAP-38 (black bars) or 25 µM forskolin (white bars) in the presence or absence of the 
PKA inhibitor H89 (10 µM) or the MEK1/2 inhibitor U0126 (10 µM) (30 min pre-treatment with 
inhibitors) and lysed after 1, 3 or 6 h (A) or after 6 h (B-D). Total RNA was extracted and 
reverse-transcribed. Transcript levels were measured by qRT-PCR. Values represent the 
grand mean ± SEM of three to four independent experiments performed in triplicates and are 
expressed as fold change of STC1 versus GAPDH mRNA. * P < 0.05, ** P < 0.01 versus 
control; one-way ANOVA, with Dunnett’s Multiple Comparison Test (A, C, D); not significantly 
different; unpaired t-test (B). 
4.3.2 PACAP and forskolin induce STC1 through ERK1/2 but not PKA in 
cultured rat cortical neurons 
Next, the induction of STC1 in primary cultures of rat cortical neurons was examined. 
Exposure of cortical neurons to 100 nM PACAP for 3 or 6 h resulted in a robust 
increase of STC1 mRNA (Fig. 23A), similar to the level of induction observed in 
NG108-15-rPAC1hop cells. The MEK1/2 inhibitor U0126 blocked the induction of 
STC1 after 6 h, whereas the PKA inhibitor H89 was without effect (Fig. 23B), which 
is in agreement with results obtained from NG108-15 cells. The AC activator 
forskolin also induced STC1 gene transcription, but unlike in NG108-15 cells, via the 
same signaling pathway used by PACAP; i.e., induction was blocked by U0126 but 
not blocked by H89 (Fig. 23C). Treatment with inhibitors only was without effect. 
These results suggest that a single signaling pathway to the STC1 gene exists in 
differentiated cortical neurons, proceeding through cAMP and the MAPK ERK1/2 but 
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not through PKA, in agreement with a cAMP dependent but PKA independent 
activation of ERK itself (see Fig. 21). 
 
 
Fig. 23: PACAP induces STC1 mRNA after 3 and 6 h in rat cortical neurons (A). 
Induction by PACAP or forskolin after 6 h is blocked by the MEK1/2 inhibitor U0126 but 
not blocked by the PKA inhibitor H89 (B+C). Cells were stimulated with 100 nM PACAP-38 
(black bars) or 25 µM forskolin (white bars) in the presence or absence of the PKA inhibitor 
H89 (10 µM) or the MEK1/2 inhibitor U0126 (10 µM) (30 min pre-treatment with inhibitors). 
Cells were lysed after 1, 3 or 6 h (A) or after 6 h (B+C). Total RNA was extracted and reverse-
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transcribed. Transcript levels were measured by qRT-PCR. Values in A represent the mean ± 
SEM of one experiment performed in triplicates. Experiment was repeated once with similar 
results. In B and C, values represent the grand mean ± SEM of five to nine independent 
experiments performed in triplicates. Values are expressed as fold change of STC1 versus 
GAPDH mRNA. * P < 0.05, ** P < 0.01 versus control; one-way ANOVA, with Dunnett’s 
Multiple Comparison Test. 
4.3.3 PACAP does not induce STC2 in cultured rat cortical neurons 
Next, the induction of the second STC paralog, STC2, was examined by qRT-PCR in 
primary cultures of rat cortical neurons. PACAP, however, failed to induce STC2 
mRNA significantly at each time point measured (1, 3 and 6 h) (Fig. 24), suggesting 
that only STC1 but not STC2 is regulated by PACAP in cortical neurons. 
 
 
Figure 24: PACAP does not induce STC2 mRNA in rat cortical neurons. Cells were 
stimulated with 100 nM PACAP-38 and lysed after 1, 3 or 6 h. Total RNA was extracted and 
reverse-transcribed. Transcript levels were measured by qRT-PCR. Values represent the 
mean ± SEM of one experiment performed in triplicates. Experiment was repeated once with 
similar results. Values are expressed as fold change of STC2 versus GAPDH mRNA. Not 
significantly different from control; one-way ANOVA, with Dunnett’s Multiple Comparison Test. 
4.3.4 PACAP induces BDNF through PKA in cultured rat cortical neurons 
Neurotrophic factors like brain-derived neurotrophic factor (BDNF) are important 
mediators of neuronal survival after brain injury. PACAP has been shown to induce 
BDNF in cultures of cortical neurons, mediating PACAP‟s protective effects against 
excitotoxic insult (Frechilla et al., 2001; Pellegri et al., 1998). Exposure to 100 nM 
PACAP induced BDNF mRNA significantly after 3 h (Fig. 25A). This induction was, 
  Results 
65 
 
unlike the induction of STC1, blocked by the PKA inhibitor H89 (Fig. 25B), 
suggesting that two potentially neuroprotective pathways co-exist in cortical neurons, 
one being PKA dependent, and another being PKA independent but ERK1/2 
dependent. 
 
Fig. 25: Induction of BDNF mRNA by PACAP is blocked by the PKA inhibitor H89 in rat 
cortical neurons. Cells were stimulated with 100 nM PACAP-38 in the presence or absence 
of the PKA inhibitor H89 (10 µM, 30 min pre-treatment). Cells were lysed after 1, 3 or 6 h (A) 
or after 3 h (B). Total RNA was extracted and reverse-transcribed. Transcript levels were 
measured by qRT-PCR. Values in A represent the mean ± SEM of one experiment performed 
in triplicates. Experiment was repeated once with similar results. In B, values represent the 
grand mean ± SEM of four independent experiments performed in triplicates. Values are 
expressed as fold change of BDNF versus GAPDH mRNA. ** P < 0.01 versus control; one-
way ANOVA, with Dunnett’s Multiple Comparison Test. 
4.4 Effects of PACAP and STC1 on neuronal survival during glutamate-
induced excitotoxicity and oxygen-glucose-deprivation (OGD) 
To investigate the neuroprotective effects of PACAP in the neuronal cell culture 
system used in this study and to determine whether the PACAP target gene STC1 
supports cell survival potentially mediating PACAP‟s neuroprotective effect, primary 
cultures of rat cortical neurons were subjected to glutamate-induced excitotoxicity and 
oxygen-glucose-deprivation (OGD), two cell culture models for ischemia and stroke. 
Excitotoxicity refers to the damaging of neurons and induction of apoptosis through 
an over-activation of excitatory glutamate receptors, specifically NMDA receptors, 
occurring after brain injury, such as stroke.  
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4.4.1 PACAP fails to prevent cell death of cultured rat cortical neurons during 
OGD and excitotoxicity 
Primary cultures of rat cortical neurons were subjected to 3 h of oxygen-glucose-
deprivation (OGD) followed by 21 h of restoration of oxygen/glucose (ROD) in the 
presence or absence of various concentrations of PACAP. The level of cell viability 
was determined by conversion of 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl-
tetrazoliumbromide (MTT), which occurs only in living cells. OGD reduced cell 
survival by approximately 40%. Unexpectedly, neither dose of PACAP tested (1, 10 
and 100 nM) reduced OGD-induced neuronal cell death (Fig. 26). 
 
 
Fig. 26: Oxygen-glucose-deprivation (OGD) causes cell death in rat cortical neurons, 
which is not prevented by PACAP treatment. Cells were subjected to 3 h of OGD in the 
presence or absence of various concentrations of PACAP-38. After 24 h neuronal viability 
was assessed by measurement of MTT conversion. Plot represents the mean ± SEM of one 
experiment performed in triplicates. Values are expressed as % survival compared to control. 
*** P < 0.001 versus control and between treatments; one-way ANOVA, with Tukey’s Multiple 
Comparison Test. 
Exposure of rat cortical neurons to 1 mM L-glutamate or 5 µM N-methyl-D-
aspartate (NMDA) for 6 or 24 h reduced cell survival by approximately 50% as 
determined by MTT conversion. Unexpectedly, 100 nM PACAP, when present 30 
min or 6 h prior to the induction of excitotoxicity and throughout the experiment, 
failed to reduce cell death (Fig. 27 A, D, E). PACAP was also without effect when 
applied simultaneously with NMDA for 6 or 24 h or when given 24 h, 2 or 6 days 
prior to a 6 h glutamate treatment (not shown). To determine whether endogenous, in 
contrast to exogenous PACAP contributes to cell survival during excitotoxicity, 
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cortical neurons were treated with NMDA for 6 or 24 h in the presence or absence of 
100 nM of the PACAP antagonist PACAP(6-38). However, PACAP(6-38) did not 
exacerbate cell death induced by excitotoxicity, suggesting that endogenous PACAP 
does not play a role in neuronal survival during excitotoxicity (Fig. 27B+F). As 
expected, the NMDA receptor antagonist (+)-MK-801 hydrogen maleate (100 nM) 
completely reversed cell death by glutamate (Fig. 27C), suggesting that glutamate-
induced cell death is mediated by activation of the NMDA receptor subfamily of 
glutamate receptors, which is in agreement with a similar effect of glutamate and 
NMDA on the induction of cell death in rat cortical neurons. These results suggest 
that, in primary cultures of cortical neurons, neither endogenous nor exogenous 
PACAP supports cell survival during short- (6 h) or long (24 h)-term excitotoxicity, 
mediated by over-activation of NMDA receptors, which is associated with stroke as 









Figure 27: Excitotoxicity induces cell death in rat cortical neurons through activation of 
NMDA receptors. PACAP is without neuroprotective effect. Cells were treated with 1 mM 
glutamate (A-C) or 5 µM NMDA (D-F) for 6 or 24 h in the presence or absence of 100 nM 
PACAP-38 (pre-treated for 30 min or 6 h), 100 nM PACAP(6-38) or 100 nM (+)-MK-801 
hydrogen maleate. Neuronal viability was assessed by measurement of MTT conversion. 
Values represent the mean ± SEM of one experiment performed in triplicates (A-D) or 
quadruplicates (F) or the grand mean of five independent experiments performed in triplicates 
(E) and are expressed as % survival compared to control. *** P < 0.001, ** P < 0.01, * P < 
0.05 versus control and between treatments; one-way ANOVA, with Tukey’s Multiple 
Comparison Test. 
4.4.2 STC1 over-expression does not prevent cell death of cultured rat cortical 
neurons during excitotoxicity 
To determine whether stanniocalcin 1 (STC1) can support neuronal survival during 
excitotoxic insult, primary cultures of rat cortical neurons over-expressing STC1 were 
generated through infection with lentiviral particles. Lentivirus was made with the 
pLVX-IRES-ZsGreen1 vector, a bicistronic lentiviral expression vector containing an 
internal ribosomal entry site (IRES) to simultaneously co-express the gene-of-interest 
(i.e., STC1) and the ZsGreen1 fluorescent protein from a single mRNA transcript. 
Neurons were infected at 4 days in vitro (div) and the expression of STC1 was 
monitored by co-expression of ZsGreen1. Six days later, cell death was induced by 1 
mM glutamate for 6 h in STC1- and ZsGreen1 only-expressing neurons and measured 
by MTT conversion. Glutamate-induced excitotoxicity reduced cell survival by 
approximately 40% in both ZsGreen1 only- and STC1-expressing neurons (Fig. 28), 
suggesting that over-expression of the putative neuroprotectant STC1 is without 
neuroprotective effect during short-term excitotoxicity in primary cultures of cortical 
neurons. 




Figure 28: Excitotoxicity-induced cell death in rat cortical neurons is not reduced by 
STC1 over-expression. Cells were infected with lentivirus expressing the ZsGreen1 
fluorescent protein only or ZsGreen1-IRES-STC1. Six days later, cells were treated with 1 
mM glutamate for 6 h and neuronal viability was assessed by measurement of MTT 
conversion. Values represent the mean ± SEM of three independent experiments performed 
in singlicates. Values are expressed as % survival compared to respective control. ** P < 
0.01, * P < 0.05 versus control; one-way ANOVA, with Tukey’s Multiple Comparison Test. 
 Propidium iodide (PI) staining was further used to assess cell death of 
neuronal cultures. PI stains nuclei of cells with disrupted plasma membranes, 
therefore staining dead or dying cells. Cells were counterstained with Hoechst 33342, 
which stains all nuclei. Neurons expressing ZsGreen1 only or STC1-IRES-ZsGreen1 
were subjected to excitotoxicity for 6 h and stained with Hoechst and PI. Cell death 
was assessed by fluorescence microscopy. Figure 29 shows the respective ZsGreen1, 
PI, Hoechst and phase contrast (PC) pictures. Treatment with 1 mM glutamate 
increased the amount of PI positive cells in both ZsGreen1 only- and STC1-IRES-
ZsGreen1-expressing neurons to about the same level. This suggests that the induction 
of cell death is not prevented by STC1 over-expression, in agreement with results 
obtained with the MTT assay. 




Figure 29: Excitotoxicity-induced cell death in rat cortical neurons is not reduced by 
STC1 over-expression. Cells were infected with lentiviruses expressing the ZsGreen1 
fluorescent protein only (A+B) or ZsGreen1-IRES-STC1 (C+D). Six days later, cells were 
treated with 1 mM glutamate for 6 h (B+D) and stained with propidium iodide (PI) and 
Hoechst 33342. At least three fluorescent pictures were taken per group and experiment was 
repeated twice with similar results. A: ZsGreen1 only, no treatment, B: ZsGreen1 only, 
glutamate treatment, C: ZsGreen1-IRES-STC1, no treatment, D: ZsGreen1-IRES-STC1, 
glutamate treatment. 




In the present study signal transduction pathways mediated by PAC1 splice variants 
of the third intracellular loop (ic3) have been characterized in neural and 
neuroendocrine cell lines. Investigations were extended to primary neurons. The 
importance of PACAP under paraphysiological and pathophysiological conditions, in 
particular its role in prolonged catecholamine (CA) secretion from adrenomedullary 
chromaffin cells and in the induction of genes in neural cells of the central nervous 
system potentially mediating PACAP‟s neuroprotective effects during ischemic stress 
has been investigated. 
 
The main new findings of this thesis are the following: 
 
(1) The hop cassette in ic3 of PAC1 is required for the induction of a maximal 
intracellular Ca
2+
 response and prolonged CA secretion from neuroendocrine 
PC12-G cells. PAC1null increases [Ca
2+
]i somewhat less and does not induce 
prolonged CA release. PAC1hip neither increases [Ca
2+
]i nor CA secretion. 
(2) PAC1hop, null and hip mediate an intracellular cAMP response in neural NG108-
15 cells, while elevation of [Ca
2+
]i occurs most efficiently in PAC1hop-, to a 
lesser extent in PAC1null-, and is absent in PAC1hip-expressing cells. 
(3) Activation of ERK1/2 by PACAP is mediated through non-canonical (PKA 
independent) cAMP dependent signaling in neural NG108-15 cells and primary 
cortical neurons. 
(4) Induction of STC1 by PACAP is dependent on ERK1/2 activation proceeding 
independently of PKA in neural NG108-15 cells and primary cortical neurons. 
(5) Neither PACAP treatment nor STC1 over-expression increases cell viability in 
neuronal cell culture models of stroke. PACAP may mediate its neuroprotective 
effects in vivo in concert with cells absent in cultures of cortical neurons, such as 
glial cells. 
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5.1 Structural basis for PAC1 receptor coupling to Ca2+ and release of 
catecholamines from neuroendocrine cells 
The neuroendocrine pheochromocytoma PC12 cell line, derived from a rat 
adrenomedullary tumor (Greene and Tischler, 1976), has long been used as a 
convenient model system for studies of the regulated dense core vesicle (DCV) 
secretory pathway (Martin and Grishanin, 2003). Elevation of intracellular Ca
2+
 
triggers release of small and large DCVs containing biogenic amines and 
neuropeptides as well as of small synaptic vesicles containing acetylcholine (ACh) 
(Bauerfeind et al., 1993; Greene and Rein, 1977; Rebois et al., 1980). 
PACAP is expressed in all cholinergic adrenomedullary nerve terminals 
(coextensive with VAChT) (Hamelink et al., 2002b). Release of ACh and PACAP 
from splanchnic nerve endings mediates short- and long-term catecholamine (CA) 
release from chromaffin cells (CCs), respectively (Watanabe et al., 1992; Watanabe et 
al., 1995). In mice lacking the PACAP gene, plasma epinephrine levels are only 
modestly reduced during the initial phase of metabolic stress (hypoglycemia) but 
more profoundly during later phases, leading to longer-lasting insulin-induced 
hypoglycemia with dose-dependent lethality. Thus, acute responses to splanchnic 
nerve activation are mediated mainly by ACh, whereas PACAP is needed for 
prolonged secretion of CAs from chromaffin cells, required for compensatory 
gluconeogenesis during periods of prolonged metabolic stress (Hamelink et al., 
2002b; Haycock, 1996). This is in agreement with studies in cultured CCs, showing 
that cholinergic activation of CA release desensitizes within a few minutes (Boksa 
and Livett, 1984), whereas PACAP-mediated release persists over longer periods of 
time (Babinski et al., 1996; Watanabe et al., 1992) and occurs under stress-mediated 
elevated splanchnic firing (Kuri et al., 2009). 
The PC12-G cell line used in this study expressed low levels of the PACAP 
receptor variants PAC1hop and PAC1hip and stimulation with PACAP triggered a 
moderate intracellular Ca
2+
 response, which is in agreement with previously published 
results (Mustafa et al., 2007; Ravni et al., 2006). The Ca
2+ 
response consisted of a 






release from intracellular stores, presumably through Gq-mediated activation of 
phospholipase Cβ (PLCβ) and IP3 receptor-mediated Ca
2+
 mobilization, which was 
followed by a prolonged Ca
2+ 
influx plateau phase. The PACAP-induced Ca
2+
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response in PC12-G cells, however, was much smaller compared to the response seen 
in primary bovine chromaffin cells (BCCs) (Hamelink et al., 2002a), suggesting that 
the low expression level of PAC1 receptors in PC12-G cells is not sufficient to drive a 
full Ca
2+
 response. BCCs express only one PACAP receptor, the PAC1hop variant 
with a full length N-terminus. Therefore, we transfected PC12-G cells with this 
bovine PAC1hop receptor (bPAC1hop) and selected a stable cell line that expressed 
bPAC1hop at physiological levels. This gave us the opportunity to study the Ca
2+
 and 
secretory pathway in cells in continuous culture with a well-defined secretory 
phenotype. We found that increasing the receptor level to physiological levels 
reconstituted a Ca
2+
 response similar to the one observed in BCCs with an increase in 
both Ca
2+
 mobilization and influx, confirming previously published data (Mustafa et 
al., 2007). The increase in the intracellular Ca
2+
 response was reflected in an increased 
secretory response. Naïve PC12-G cells responded to PACAP treatment with a low-
level release of CAs, which did not exceed the phase of acute secretion (0-5 min). 
Expression of bPAC1hop increased acute secretion and, more importantly, conferred 
prolonged secretion, which lasted for more than one hour. These data suggest that 
physiological levels of the PAC1hop receptor are needed for PACAP‟s long-term 
effects on CA secretion from adrenomedullary chromaffin cells, required for 
PACAP‟s homeostatic effects in vivo during prolonged periods of stress. Previous 
studies have demonstrated the ability of PACAP to induce a robust Ca
2+
 response and 
prolonged CA secretion in naïve PC12 cells (Taupenot et al., 1999), which is likely 
due to a higher expression of PAC1hop than in PC12-G cells (Cavallaro et al., 1995). 
The PACAP-mediated acute and prolonged secretory response are mediated via 





 channels (VGCCs), whereas sustained secretion involves 
a Gq/PLCß/store-operated Ca
2+
 channel (SOCC) pathway (Mustafa et al., 2010; 
Taupenot et al., 1999). The importance of PLCß activation in sustained release is in 
agreement with a predominant role of the PAC1hop receptor which engages dual 
signaling through adenylate cyclases (ACs) and PLCß. 
All PACAP receptors couple to ACs through Gs and endogenous PAC1 
receptors in PC12-G cells are maximally coupled to ACs so that expression of 
bPAC1hop does not further increase intracellular cAMP generation (Mustafa et al., 
2007). PACAP-mediated signaling through cAMP and the cAMP dependent protein 
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kinase (PKA) is important in the sustained activation and mRNA elevation of tyrosine 
hydroxylase (TH), the rate-limiting enzyme in CA biosynthesis. PKA regulates the 
activity of TH by phosphorylation at Ser40 and by increasing its transcription to 
maintain CA stores for subsequent release (Bobrovskaya et al., 2007; Corbitt et al., 
1998; Haycock, 1996). The PKA-mediated effect on TH activity is modulated by 
PKC and Ca
2+
 (Corbitt et al., 2002; Marley et al., 1996; Rius et al., 1994), indicating a 
dual role for Gq-mediated signaling by PACAP in sustained secretion: modulation of 
TH levels and activity to maintain CA stores and mediating their subsequent release. 
PKC activation has also been shown to increase the size of the readily 
releasable pool (RRP) in CCs leading to enhanced exocytosis upon depolarization 
(Gillis et al., 1996; Vitale et al., 1995). This could account for the increased 
depolarization-evoked secretion in PC12-G cells expressing the bPAC1hop receptor 
observed in the present study. 
Chromaffin cells of the rodent adrenal gland express three isoforms of the 
PAC1 receptor, PAC1hop, null and hip, with PAC1hop being the most abundant 
variant (Nogi et al., 1997; Stroth, 2010; Ushiyama et al., 2007). Thus, experiments 
were extended to PC12-G cells expressing the three rat PAC1 variants, respectively. 
We generated PC12-G cells, expressing the rat PAC1hop, null or hip variant with a 
full-length N-terminus through infection with gammaretroviral vectors to generate 
cell lines stably expressing the respective receptor variant at similar densities. 
Increasing the expression of the rPAC1hop receptor increased the PACAP-mediated 
Ca
2+
 response to a level similar to the response seen in bPAC1hop-expressing PC12-
G cells. The receptor not expressing any insert in the third intracellular loop (ic3), 
PAC1null, evoked a similar Ca
2+
 response, with an only somewhat smaller initial rise 
in Ca
2+
. The receptor expressing the hip cassette in ic3, PAC1hip, did not increase the 
low-level Ca
2+
 response observed in naive PC12-G cells, suggesting that expression 
of the hip cassette abolishes coupling to Ca
2+
. Expression of either PAC1hop or null 
increased the acute secretory response, whereas only PAC1hop conferred sustained 
CA release. PAC1hip was without effect, in agreement with a lack of increasing the 
intracellular Ca
2+
 response. These results suggest that the PAC1hop receptor is the 
only variant mediating prolonged CA release. The slightly higher rise in the initial 
Ca
2+
 response, presumably Ca
2+
 mobilization, by PAC1hop compared to PAC1null 
may be important in mediating a prolonged secretory response which is, as mentioned 
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above, dependent on PLCß-mediated signaling. It will be of particular interest to 
investigate whether the Ca
2+
 influx plateau phase in PAC1hop- and PAC1null-
expressing PC12-G cells is mediated by different Ca
2+
 channels. Perhaps PAC1null 
fails to activate store-operated Ca
2+
 entry (SOCE) and therefore fails to mediate 
prolonged release of DCVs. Taken together we provide evidence that PACAP-
mediated signaling through PAC1hop, the predominant PACAP receptor in CCs of 
the adrenal gland in vivo, mediates a Ca
2+
 and secretory response, required for 
sustained CA secretion to restore homeostasis during prolonged periods of stress. 
5.2 Second messenger generation and MAPK activation in 
differentiated and undifferentiated cells of the central nervous 
system 
5.2.1 Structural basis for PAC1 receptor coupling to second messenger 
generation in undifferentiated NG108-15 cells 
In addition to PACAP‟s function as a neuropeptide slow transmitter at the peripheral  
splanchnico-adrenomedullary synapse regulating prolonged DCV release from CCs 
during stress-responding, PACAP acts as an important neurotrophic factor during 
brain development and as a neuroprotective factor during brain injury (Arimura, 1998; 
Mustafa and Eiden, 2006; Ohtaki et al., 2008; Shioda et al., 2006). As mentioned 
above, activation of its cognate receptor PAC1 results in induction of combinatorial 
signaling through coupling to Gαs and Gαq and insertions in the third intracellular 
loop of the receptor modulate the efficacy of G protein coupling. Studies in 
heterologous non-neural cells show that the presence of the hip cassette in PAC1 
interferes with G protein coupling (Lutz et al., 2006; Pisegna and Wank, 1996; 
Spengler et al., 1993), in agreement with results obtained from heterologous PC12-G 
cells in the present study. Multiple signaling pathways regulate neural differentiation 
and survival (Ohtaki et al., 2008; Shioda et al., 2006; Vaudry et al., 2002a), however, 
the functional importance of different PAC1 variants in engaging different signaling 
pathways in neural cells has not been previously delineated. 
 We chose the mouse neuroblastoma x rat glioma NG108-15 cell line to 
investigate PAC1-mediated signaling, because these cells, unlike PC12 cells, do not 
respond to PACAP endogenously but respond to other GPCR ligands (Hamprecht et 
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al., 1985), therefore providing an appropriate model system to study the different 
PAC1 splice variants separately introduced into a neural cell line. NG108-15 cells 
were transduced with the three major PAC1 splice variants of the adult nervous 
system, the PAC1null, hop1 and hip variant with a full-length N-terminus, by 
gammaretroviral infection and the PACAP-induced cAMP and Ca
2+ 
response was 
measured. We found that PACAP triggered intracellular cAMP generation in all three 
cell lines. Maximal cAMP generation by 100 nM PACAP-38 was greater in 
PAC1hop- and null- compared to hip-expressing cells, which supports results 
generated from rat and human PAC1 splice variants expressed in non-neural cell lines 
(Lutz et al., 2006; Spengler et al., 1993). The PACAP-induced Ca
2+ 
response 
consisted of a rapid and transient rise in [Ca
2+
]i indicative of Ca
2+ 
release from 
intracellular stores, which was not followed by a prolonged Ca
2+ 
influx plateau phase 
observed in BCCs (Hamelink et al., 2002a), cortical neurons (Grimaldi and Cavallaro, 
1999) and PC12 cells (this study). The intracellular Ca
2+ 
response in NG108-15 cells 
expressing the bovine PAC1hop receptor has been shown to be mainly mediated 
through IP3 receptor-activated Ca
2+ 
mobilization (Mustafa et al., 2007), which is 
likely to also apply for the PAC1-mediated Ca
2+ 
response measured here. Our results 
show that PAC1 receptor expression in NG108-15 cells reconstitutes cAMP and Ca
2+ 
signaling, presumably through coupling to Gs and Gq, respectively. A Ca
2+ 
response 
was induced by PAC1hop and null but not hip and the increase in [Ca
2+
]i was greater 
in PAC1hop- than in PAC1null-expressing cells, in agreement with results obtained 
from heterologous PC12-G cells. This suggests that expression of the hop cassette in 
the third intracellular loop is required for the maximal induction of cAMP and Ca
2+ 
combinatorial signaling. Expression of no cassette in ic3 as in PAC1null supports a 
reduced coupling to Ca
2+ 
relative to PAC1hop, while the receptor with the hip cassette 
supports no measurable coupling to Ca
2+ 
at all. 
It has previously been shown that cAMP and Ca
2+
 combinatorial signaling is 
required for PACAP target gene induction (Girard et al., 2004; Hamelink et al., 
2002a; Hashimoto et al., 2000) and involved in PACAP‟s neurotrophic and 
neuroprotective effects (Onoue et al., 2002b; Pugh and Margiotta, 2006; Tanaka et al., 
1997; Vaudry et al., 2000a) in neuroendocrine and neural cells of the peripheral and 
central nervous system. PAC1 splice variant-specific immediate-early gene induction 
occurs in heterologous non-neural cells (Pisegna et al., 1996). Our results indicate that 
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PAC1 splice variant-specific expression, resulting in differential second messenger 
generation, is a regulatory mechanism by which PACAP mediates its pleiotropic 
effects in the nervous system, such as during development and during stress-
responding throughout adulthood. 
5.2.2 PACAP-mediated second messenger production in differentiated neurons 
PACAP‟s neuroprotective effects in the central nervous system in vivo, specifically 
after middle cerebral artery occlusion (MCAO) producing cortical infarction (Chen et 
al., 2006; Ohtaki et al., 2006; Reglodi et al., 2000; Reglodi et al., 2002; Tamas et al., 
2002) suggests that activation of PAC1 and respective signal transduction pathways 
mediate this effect. We found that cultures of rat cortical neurons predominantly 
expressed the PAC1null and hop receptor variants and low levels of PAC1hip, 
VPAC1 and VPAC2 receptors, in agreement with previously published reports 
showing a predominant PAC1hop and null expression in the human and rat brain and 
neuronal cells of various brain regions including the cerebral cortex (Cavallaro et al., 
1996; Lutz et al., 2006; Nogi et al., 1997; Pisegna and Wank, 1996; Zhou et al., 
2000). PACAP stimulation of cortical cultures triggered a robust intracellular cAMP 
production that was ~60% of the maximal cAMP production generated by direct 
supramaximal stimulation of adenylate cyclases (ACs) with 25 μM forskolin, 
suggesting that PAC1 receptors in differentiated cortical neurons are efficiently 
coupled to ACs, in agreement with a high endogenous expression level of PAC1hop 
and null receptors in these cells. The PACAP-evoked Ca
2+
 response consisted of a 
robust initial burst of Ca
2+
 mobilization, presumably Ca
2+
 release from IP3 sensitive 
intracellular stores, followed by prolonged Ca
2+
 influx, in agreement with previously 
published results (Grimaldi and Cavallaro, 1999). Only ~75% of all cells responded to 
PACAP with a robust increase in [Ca
2+
]i, whereas the remaining 25% showed only a 
weak or no response. This indicates that a fraction of the cell population expresses no 





 inefficiently, such as the PAC1hip or PAC1null receptor variant, 
respectively. It has been shown that PACAP fails to stimulate an intracellular Ca
2+
 
response in cortical precursors endogenously expressing the PAC1null receptor, 
whereas ectopic expression of PAC1hop confers a PACAP-mediated rise in [Ca
2+
]i 
(Lu et al., 1998; Nicot and DiCicco-Bloom, 2001). Only ~15% of the cells that 
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responded to PACAP with a rise in [Ca
2+
]i responded to depolarizing concentrations 
of KCl with Ca
2+
 entry; this cell population seemed to respond to PACAP with Ca
2+
 
mobilization only, lacking an obvious Ca
2+
 influx plateau phase. In the majority of 
cells, KCl did not stimulate Ca
2+
 influx. It is noteworthy that, without previous 
PACAP treatment, the majority of cells responded to KCl with Ca
2+
 entry (not 
shown), suggesting that PACAP receptor activation inhibits VGCCs. In the 25% of 
cells not showing any Ca
2+
 response to PACAP, subsequent stimulation resulted in a 
robust Ca
2+
 influx upon depolarization (not shown). These results suggest, that 




 influx) inhibits subsequent 
KCl-mediated Ca
2+
 influx through VGCCs in the majority of cortical neurons. 
Alternatively, specific βγ subunits coupled to PAC1hop may have the same effect 
(Garcia et al., 1998). Inhibition of N-type VGCCs by VIP has been previously shown 
in sympathetic neurons via a pertussis toxin-insensitive G protein-mediated pathway 
(Zhu and Ikeda, 1994; Zhu and Yakel, 1997). It will be interesting to investigate 
whether sub-populations of cortical neurons express different variants of the PAC1 
receptor and whether PACAP-mediated signaling specifically regulates a certain type 
of VGCCs expressed in the majority of cortical neurons, such as the L-, N- or P/Q-
type (Hofmann et al., 1994). 
5.2.3 Signaling to ERK activation in undifferentiated NG108-15 cells and 
differentiated neurons 
PACAP‟s neurotrophic effects in PC12 cells are mediated through activation of the 
mitogen-activated protein kinase (MAPK) extracellular signal-regulated kinase (ERK) 
pathway (Vaudry et al., 2002d). ERK activation regulates diverse cellular processes 
such as proliferation, differentiation and apoptosis. Intensity and spatio-temporal 
activation are key determinants in generating precise biological responses (Marshall, 
1995; Pouyssegur and Lenormand, 2003; Sebolt-Leopold and Herrera, 2004). Cyclic 
AMP signaling is implicated in the regulation of ERK activation both positively and 
negatively depending on the cell type (Dumaz and Marais, 2005). 
In undifferentiated NG108-15 cells expressing the PAC1hop receptor variant, 
PACAP treatment resulted in the activation of both cAMP and Ca
2+ 
signaling, and a 
rapid and transient activation of ERK. ERK activation was blocked by 
pharmacological inhibition of ACs with 2ʹ5ʹ-dideoxyadenosine (ddAd) but was not 
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induced by cAMP generation through AC activation by forskolin, indicating that 
cAMP generation is required but not sufficient to activate ERK. These results suggest 
that maximal activation of ERK requires combinatorial signaling in this cell type and 
can therefore only be supported by the PAC1hop receptor variant. Preliminary data 
support this conclusion insofar that ERK activation in NG108-15 cells was greatest 
when the PAC1hop receptor was expressed, moderate in PAC1null- and suppressed in 
PAC1hip-expressing cells; also, inhibitors of the Ca
2+ 
pathway, such as calcineurin 
and PKC inhibitors, blocked PAC1hop-mediated ERK activation. Activation of ERK 
upon PAC1hop activation was not blocked by PKA inhibition with H89, suggesting a 
cAMP-mediated pathway independently of the canonical cAMP effector PKA. This 
non-canonical cAMP pathway was previously described in pheochromocytoma PC12 
(Ravni et al., 2008) and neuroblastoma SH-SY5Y cells (Monaghan et al., 2008), 
mediating PACAP‟s neurotrophic effects leading to neurite extension. 
 In differentiated cortical neurons, PACAP activated ERK1/2 in a rapid and 
sustained fashion, which was also blocked by AC but not PKA inhibition, therefore 
proceeding through this non-canonical cAMP pathway (i.e., independently of PKA) 
as well. High concentrations of the AC inhibitor ddAd were required to block ERK 
activation in cortical neurons, suggesting that very low concentrations of cAMP are 
sufficient to signal to ERK in these cells. PACAP-mediated ERK activation was, in 
contrast to NG108-15 cells, mimicked by the AC activator forskolin, which was also 
not blocked by inhibition of PKA with H89. These results suggest that cAMP is 
required and sufficient to engage a non-canonical (PKA independent) signaling 
pathway in cortical neurons to activate ERK. In differentiated CNS neurons, cAMP 
signaling seems to be efficiently coupled to this novel PKA independent pathway, 
whereas in less differentiated neural cells, as shown for NG108-15 cells, a co-factor, 
presumably Ca
2+
, is required to engage this pathway. 
5.3 Signaling to neuroprotective target genes in undifferentiated 
NG108-15 cells and differentiated neurons 
In differentiated neurons, the MAPK/ERK pathway has been implicated in cell 
survival, e.g., following excitotoxic or hypoxic/ischemic injury (Elliott-Hunt et al., 
2002; Gonzalez-Zulueta et al., 2000; Hetman and Gozdz, 2004; Hetman et al., 1999; 
Irving et al., 2000; Jin et al., 2002). The importance of ERK in mediating PACAP‟s 
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neuroprotective effects has been shown in cerebellar granule cells during K
+
 
deprivation (Villalba et al., 1997), and in parasympathetic (Pugh and Margiotta, 2006) 
and sympathetic neurons during growth factor withdrawal (May et al., 2010). The 
importance of ERK in the activation of PACAP target genes, potentially mediating 
PACAP‟s neuroprotective effects in the CNS, still remains to be delineated. 
Here we show that PACAP induced stanniocalcin 1 (STC1) mRNA in NG108-
15-rPAC1hop cells and rat cortical neurons. We previously identified STC1 as a 
PACAP target gene in PC12-G cells expressing physiological levels of the bovine 
PAC1hop receptor (PC12-bPAC1hop) and in primary BCCs (Ait-Ali et al., 2010). 
STC1 is upregulated during neuronal differentiation and the pathological condition of 
hypoxia/ischemia (Westberg et al., 2007a; Westberg et al., 2007b; Zhang et al., 2000; 
Zhang et al., 1998), therefore being a candidate target gene for mediating PACAP‟s 
neurotrophic effects in the central nervous system. PACAP-mediated STC1 induction 
was blocked by the MEK1/2 inhibitor U0126 in both NG108-15-rPAC1hop cells and 
cortical neurons, suggesting that the activation of ERK1/2 is required for STC1 
induction by PACAP. The PKA inhibitor H89 failed to block STC1 induction by 
PACAP, indicating a PKA independent signaling pathway to the STC1 gene, in 
agreement with a PKA independent activation of ERK. In NG108-15-rPAC1hop cells, 
the AC activator forskolin also induced STC1 gene transcription, although it failed to 
activate ERK. Induction was blocked by H89, suggesting that two cAMP pathways 
for STC1 induction co-exist in this undifferentiated cell line. Non-canonical cAMP 
signaling to STC1 induction via ERK seems to require combinatorial signaling 
through cAMP and Ca
2+
 in these cells, which is mediated by PAC1hop and to a lesser 
extent by PAC1null, whereas canonical cAMP signaling to STC1 induction is 
activated through cAMP generation only, as mediated by pharmacological activation 
of ACs or activation of the PAC1hip variant. In cortical neurons, the AC activator 
forskolin activated the same signaling pathway as PACAP and induced STC1 via 
ERK but not PKA, suggesting that STC1 gene transcription is restricted to a single 
(non-canonical) cAMP signaling pathway in these differentiated cells. Activation of 
this non-canonical pathway and induction of certain genes may be involved in 
PACAP‟s cAMP dependent neuroprotective effects during excitotoxicity (Morio et 
al., 1996; Said et al., 1998; Shintani et al., 2005) and hypoxia/ischemia in neuronal 
cell culture (Stumm et al., 2007) and during stroke in vivo (Chen et al., 2006). 
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PACAP also activated the canonical cAMP/PKA pathway to induce the neurotrophin 
BDNF. BDNF has been implicated in PACAP‟s neuroprotective effects (Frechilla et 
al., 2001), suggesting that non-canonical and canonical cAMP signaling co-exist in 
CNS neurons mediating PACAP‟s neuroprotective effects in vivo. However, the 
selective pharmacological activation of a cAMP pathway not involved in 
physiological processes such as learning and memory might reduce the detrimental 
side effects of drugs targeting the cAMP/PKA pathway (Arnsten et al., 2005; Kandel, 
2001; Kuo and Greengard, 1969). 
 
Figure 30: Schematic representation of PAC1hop-mediated signaling in cells of the 
central nervous system. PACAP-mediated activation of its receptor PAC1 expressing the 
hop cassette in the third intracellular loop results in activation of the two G proteins Gq and 
Gs, thereby inducing combinatorial signaling through cAMP and calcium. In less differentiated 
NG108-15 cells, combinatorial signaling is required for ERK activation (indicated by the yellow 
arrow), whereas in differentiated CNS neurons, activation of the cAMP pathway is sufficient to 
activate ERK. ERK activation is independent of the canonical cAMP effector PKA. Non-
canonical cAMP signaling activates the STC1 gene, whereas cAMP/PKA signaling induces 
BDNF. 
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5.4 PACAP and neuroprotection 
PACAP‟s neuroprotective effects during stroke and other neurodegenerative diseases 
in vivo and under various conditions promoting apoptosis in cell culture (vide supra) 
were sought to be confirmed in cell culture models of stroke. Brain injury caused by 
transient or permanent focal brain ischemia (stroke) develops from a complex 
sequence of pathophysiological events. Reduced supply of oxygen and glucose 
through inadequate blood supply triggers energy deficits and membrane potential 
changes, eventually causing neuronal depolarization. Increasing [Ca
2+
]i activate the 
release of excitatory amino acids like L-glutamate, which accumulate in the 
extracellular space causing over-activation of ionotropic and metabotropic glutamate 
receptors. Ionic imbalances, especially Ca
2+
 overload through activation of ionotropic 
NMDA receptors, cause neuronal damage (Dirnagl et al., 1999; Martin et al., 1994; 
Sattler and Tymianski, 2001). 
 We subjected primary cultures of rat cortical neurons to oxygen-glucose-
deprivation (OGD) and glutamate-induced excitotoxicity in the presence or absence of 
PACAP and measured neuronal viability through MTT conversion. Both OGD and 
excitotoxicity caused neuronal cell death. However, PACAP treatment failed to 
increase cell survival under both conditions. These results were very unexpected 
because PACAP has been previously shown to rescue neurons from OGD- (Stumm et 
al., 2007) and excitotoxicity-induced cell death (Frechilla et al., 2001; Morio et al., 
1996; Shintani et al., 2005). The biological significance of STC1 and the importance 
of the non-canonical cAMP pathway in neuroprotection are still awaiting clarification; 
however, PACAP also induced the neurotrophic factor BDNF through activation of 
the canonical cAMP/PKA pathway. PACAP has been previously shown to induce the 
expression of BDNF during excitotoxicity in cortical neurons, increasing cell survival 
(Frechilla et al., 2001; Pellegri et al., 1998; Shintani et al., 2005) and to activate PKA 
in various cell types, mediating PACAP‟s neurotrophic and neuroprotective effects 
(Kienlen Campard et al., 1997; May et al., 2010; Onoue et al., 2002b; Pugh and 
Margiotta, 2006; Shoge et al., 1999; Stetler et al., 2010; Tanaka et al., 1997; 
Tomimatsu and Arakawa, 2008; Vaudry et al., 1998a; Villalba et al., 1997). The 
results of the present study indicate that activation of PACAP-mediated signaling 
pathways and induction of neurotrophic target genes do not increase the survival of 
cultured cortical neurons exposed to excitotoxicity or OGD. 
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It has been shown that PACAP increases neuronal survival during mild (90 
min) OGD at concentrations below 20 nM, whereas it exacerbates cell death at 100 
nM. Both low and high concentrations of PACAP activate ERK and PACAP‟s 
protective effect is dependent on the activation of ERK (Stumm et al., 2007), 
suggesting that high levels of cAMP or the activation of a second signaling pathway 
by high concentrations of PACAP exacerbate cell death, e.g., via activation of the p38 
MAPK pathway (Stumm et al., 2007). PACAP has a high potency for cAMP 
generation (EC50 value near 1 nM) but a lower potency for inositol phosphate (InsP) 
production (approximately 1 log less) (Deutsch and Sun, 1992; Grimaldi and 
Cavallaro, 1999; Spengler et al., 1993); co-activation of PLCβ-mediated signaling at 
higher concentrations of PACAP might interfere with cAMP-mediated protection of 
CNS neurons. We therefore subjected cortical neurons to 3 h of OGD, causing 
approximately 40% cell death after 24 h, in the presence or absence of various 
concentrations of PACAP. However, every concentration tested (1, 10 and 100 nM 
PACAP) failed to either increase cell survival or exacerbate cell death caused by 
OGD. 
PACAP has also been shown to promote neuronal survival during glutamate-
induced excitotoxicity. In cultures of rat cortical neurons, exogenous PACAP is 
protective during short-term excitotoxicity (6 h)  between 0.1 pM and 1 nM (Morio et 
al., 1996) and during long-term excitotoxicity (18 h) between 1 pM and most 
efficiently 100 nM (Frechilla et al., 2001). The PACAP antagonist PACAP(6-38) 
exacerbates cell death induced by acute glutamate exposure after 24 and more 
prominently after 48 h (Shintani et al., 2005). Cyclic AMP and BDNF have both been 
implicated in PACAP‟s neuroprotective effects during excitotoxicity. We subjected 
cultures of rat cortical neurons to short-term (6 h) and long-term (24 h) excitotoxicity 
in the presence or absence of PACAP (100 nM) or the PACAP antagonist PACAP(6-
38) and found that neither PACAP increased nor PACAP(6-38) decreased cell 
survival, suggesting that neither exogenous nor endogenous PACAP is protective 
during short- or long-term excitotoxicity. 
Both endogenous and exogenous PACAP have been shown to be protective 
during stroke in vivo and PACAP is even effective when administered after the onset 
of ischemia (Chen et al., 2006; Reglodi et al., 2000), suggesting that PACAP-
activated signaling molecules and target genes represent promising targets for 
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therapeutic intervention after brain damage. However, our results indicating that 
PACAP does not increase survival in neuronal cell culture models of stroke must first 
be reconciled both with the demonstrable neuroprotective effect of PACAP during 
stroke in vivo and the reports in the literature showing that PACAP treatment does in 
fact ameliorate excitotoxic and hypoxic/ischemic cell death in cultured rodent cortical 
neurons. One possibility is that PACAP may mediate its neuroprotective effect in vivo 
via cells absent in cultures of cortical neurons, dependent on the type of preparation 
employed. In astrocytes, picomolar concentrations of PACAP trigger cAMP 
dependent ERK activation stimulating proliferation (Hashimoto et al., 2003; Moroo et 
al., 1998). Neuron-derived PACAP stimulates glutamate uptake in astrocytes (Figiel 
and Engele, 2000), suggesting that glial regulation of excess extracellular glutamate 
decreases neurodegeneration caused by excitotoxicity. PACAP also stimulates 
production of the neurotrophic cytokine IL-6 in astrocytes (Gottschall et al., 1994; 
Tatsuno et al., 1996; Van Wagoner and Benveniste, 1999), suggesting that PACAP 
release during injury mediates astrocyte proliferation (gliosis) and IL-6 secretion, 
thereby increasing neuronal survival. This conclusion is supported by in vivo data 
showing that PACAP decreases ischemic cell death in association with IL-6 (Ohtaki 
et al., 2006). PACAP has also been shown to be involved in controlling the immune 
response required for peripheral nerve regeneration after injury (Armstrong et al., 
2008), which likely also applies for CNS injury. PACAP inhibits the production of 
pro-inflammatory cytokines and stimulates the production of anti-inflammatory 
cytokines in activated macrophages and microglia, and promotes differentiation of 
anti-inflammatory T helper 2 cells (Th2), thereby deactivating and eliminating 
stimulated immune cells to limit tissue damage associated with the immune response 
after injury (Delgado et al., 2003a). Inflammation accompanies and exacerbates most 
brain pathologies and PACAP‟s anti-inflammatory action in the central nervous 
system (Kong et al., 1999) most likely promotes regeneration after CNS damage 
induced by traumatic brain injury (TBI), stroke and other neurodegenerative diseases 
(Delgado et al., 2003b). It is therefore highly relevant to future work in this area to 
determine whether PACAP supports neuronal survival in cortical neuron/glia co-
cultures subjected to OGD or glutamate-induced excitotoxicity and whether cell death 
in neuronal cultures is reduced by treatment with conditioned medium from PACAP-
treated astrocyte cultures. 
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5.5 Stanniocalcin 1 and neuroprotection 
Stanniocalcin 1 (STC1) is abundantly expressed in differentiated brain neurons 
(Zhang et al., 1998). It is upregulated in vivo following ischemia and it increases 
neural cell resistance to hypoxic insult upon over-expression in cell culture (Zhang et 
al., 2000). STC1, as a PACAP target gene, was therefore an important candidate as a 
mediator of PACAP‟s neuroprotective effects during stroke in vivo. To determine 
whether STC1 has neuroprotective properties, we over-expressed STC1 in primary 
cultures of rat cortical neurons and determined cell survival after excitotoxic insult. 
STC1 over-expression in neurons was achieved by infection with lentiviruses, which 
efficiently infect non-dividing cells. Excitotoxicity was induced with high 
concentrations of glutamate for 6 h, reducing cell survival by approximately 40% in 
both STC1- and mock-transduced neurons. These results indicate that over-expression 
of STC1 does not confer increased resistance to excitotoxic insult. STC1 over-
expression has previously been shown to protect against hypoxic insult, induced by 
CoCl2 treatment leading to Ca
2+
 influx, in human neural crest-derived Paju cells. 
Moreover, STC1 expression is increased in the penumbra zone following ischemic 
insult in the rat brain (Zhang et al., 2000), suggesting that increased STC1 expression 
confers neuronal survival during excitotoxicity. Our results were therefore unexpected 
and reinforce the notion that the excitotoxic cell culture model employed by our 
laboratory and others may not be appropriate to examination of neuroprotective 
effects of either STC1 or PACAP observed in vivo. 
 It is possible that STC1 is released from neurons to regulate intermediate cells 
in a paracrine fashion such as macrophages and endothelial cells, reducing 
inflammatory responses (Chakraborty et al., 2007; Chen et al., 2008; Sheikh-Hamad, 
2010; Wang et al., 2009) and thereby ameliorating brain damage associated with 
inflammation in brain pathologies such as TBI (Long et al., 2003) and stroke (Zhang 
et al., 2000). The STC1-related protein STC2 has been shown to reduce endotoxin-
mediated microglial activation and neuronal loss following excitotoxicity associated 
with ER stress (Byun et al., 2010). STC2, but not STC1, is induced by the unfolded 
protein response (UPR), a critical component of cell survival during ER stress (Ito et 
al., 2004). STC2 was not induced by PACAP in cortical neurons, as shown in the 
present study. It is possible that STC1 is up-regulated during brain injury 
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independently of the UPR to reduce inflammatory responses and thus increase 
neuronal survival analogous to the function of its paralog during ER stress. 
5.6 Limitations of the NMDA cell culture model for neurodegenerative 
diseases 
The theory that high concentrations of glutamate destroy neurons was established 
more than five decades ago (Lucas and Newhouse, 1957; Olney and Sharpe, 1969). 
Ca
2+
 influx through activation of the NMDA subtype of glutamate receptors was 
suggested as the main mediator of ischemia-induced excitotoxicity in the 1980s, based 
on a plethora of pharmacological and cell biological data obtained both in culture and 
in vivo (Choi and Rothman, 1990; Simon et al., 1984). However, in 2001, evaluation 
of all of the many clinical trials for stroke involving NMDA receptor antagonists led 
to the conclusion that they were uniformly ineffective for this therapeutic application 
(Albers et al., 2001; Sacco et al., 2001). With the approval of tissue plasminogen 
activator (tPA) for the treatment of acute ischemic stroke in 1996, treatment still 
remains limited to thrombolysis (Lee et al., 1999). Effective neuroprotective and 
restorative drug therapies for acute stroke and other neurodegenerative disorders are 
still lacking. 
 It was subsequently suggested that one of the main difficulties with the use of 
NMDA receptor antagonists as neuroprotectants in clinical trials of stroke was due to 
the short neuroprotective time window (Ikonomidou and Turski, 2002), as previously 
shown in rodent stroke models (Ma et al., 1998). It was hypothesized that acutely 
increased extracellular glutamate concentrations after brain injury might be 
neurotoxic, whereas moderately sustained glutamate elevation could actually be 
physiologically important in sustaining neuronal survival. NMDA receptor 
antagonists might therefore only be effective when administered prior to or shortly 
after the insult which is unlikely in a clinical emergency setting. In addition, NMDA 
receptor antagonists might actually exacerbate neuronal damage if administered 
during an inappropriate time window following stroke. NMDA receptors are not only 
localized synaptically but also extrasynaptically. Activation of synaptic NMDA 
receptors promotes neuronal survival via activation of the transcription factor cAMP 
response element binding protein (CREB) and induction of neuroprotective genes 
such as BDNF and bcl-2, whereas anti-survival signaling mediated by activation of 
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extrasynaptic NMDA receptors antagonizes this effect. Neuroprotective therapies for 
the treatment of pathological conditions associated with glutamate toxicity should 
therefore enhance synaptic activity and disrupt extrasynaptic NMDA receptor-
mediated signaling. The low-affinity NMDA receptor blocker memantine has been 
shown to preferentially antagonize extrasynaptic NMDA receptors (Leveille et al., 
2008) and to reduce clinical deterioration in moderate to severe Alzheimer‟s disease 
(Reisberg et al., 2003; Tariot et al., 2004). Drugs acting on NMDA receptors are still 
potential therapeutic agents for neurodegeneration. Synaptic versus extrasynaptic 
NMDA receptor activation, receptor composition of different subunits and activation 
of different downstream signaling molecules provide the basis for future 
developments of NMDA receptor-mediated neuroprotective therapies (Hardingham 
and Bading, 2010; Kemp and McKernan, 2002). 
 The complexity of NMDA receptor-activated signaling in neuronal survival 
and death clearly shows the problems one faces in modeling complex brain 
pathologies such as stroke in cell culture. Moreover, the outcome of therapeutic 
intervention in stroke patients and animal models of stroke are often inconsistent, 
successful in animal models but not in clinical trials, which might be due to high 
variability in clinical stroke patients. Rigorous preclinical testing is required for novel 
neuroprotective drugs to have the potential to succeed in a clinical trial (1999). 
5.7 Concluding remarks and future directions 
Evidence from numerous mouse models of permanent and transient ischemia, and 
various cell culture models of excitotoxicity and hypoxia/ischemia by several 
independent laboratories indicate a clinical importance of PACAP in stroke. PACAP 
has a reasonable chance to succeed in an appropriately designed clinical trial (1999). 
PACAP prevents neuronal death at picomolar to nanomolar concentrations; it is 
transported across the blood-brain barrier (BBB) (Banks et al., 1993; Banks et al., 
1996) and is neuroprotective after ischemic injury when administered intravenously 
(i.v.), indicating that its transport across the BBB is sufficient to provide enough 
peptide to the brain, in particular to the tissue at risk, to prevent cell death. Moreover, 
PACAP has a wide therapeutic time window, supporting neuronal survival when 
administered immediately prior to until up to several hours after the onset of ischemia, 
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indicating its effectiveness during the acute phase of stroke as well as during 
secondary neuronal damage following stroke. 
PACAP‟s widespread expression in the CNS and involvement in a plethora of 
physiological functions indicates that pharmacological modulation of downstream 
signaling molecules results in more precise control over neurodegenerative cell loss 
with a reduction in adverse effects. PACAP activates different GPCRs resulting in the 
activation of different signaling pathways such as Gs- and Gq-mediated signaling. 
Canonical cAMP signaling links cAMP through PKA to CREB activation and gene 
induction, inducing long-lasting changes in the cell. This cAMP/PKA signaling 
pathway, activated by Gαs coupled to ACs, is involved in many physiological 
processes such as learning and memory. In addition to activating this cAMP pathway, 
PACAP also activates so called non-canonical cAMP signaling (independent of 
PKA). We provide evidence for the existence of non-canonical cAMP signaling in 
CNS neurons to ERK1/2 activation and STC1 gene induction. Both canonical and 
non-canonical cAMP signaling may work together during brain injury. However, the 
selective pharmacological activation of a cAMP pathway not involved in 
physiological processes such as learning and memory might reduce adverse effects of 
drugs targeting the cAMP/PKA pathway. 
Activation of this novel cAMP pathway in less differentiated cells of the CNS 
is supported by combinatorial signaling through cAMP and Ca
2+
 uniquely mediated 
by the PAC1hop receptor variant. PAC1hop-mediated combinatorial signaling is also 
required for prolonged CA secretion from adrenomedullary chromaffin cells, thereby 
mediating PACAP‟s homeostatic responses to prolonged stress in the PNS and 
determining whether an animal survives or not under these paraphysiological 
conditions (Hamelink et al., 2002b). Taken together, the results of the present study 
clearly show the importance of the neuropeptide slow transmitter PACAP and its 
cognate GPCR PAC1hop in mediating combinatorial signaling through cAMP and 
Ca
2+
 important during stress-responding in the peripheral and central nervous system. 
Further studies are required to reconfirm the neuroprotective effects of 
PACAP and to specifically elucidate the mechanisms of its neuroprotective actions. It 
will be of paramount importance to understand whether PACAP has a direct 
neuroprotective effect or regulates intermediary cells such as glial cells in a paracrine 
fashion to confer neuroprotection indirectly. The results of the present study favor at 
  Discussion 
89 
 
this time an indirect neuroprotective pathway for PACAP. Highly relevant future 
experiments include the direct comparison of PACAP‟s neuroprotective potential in 
cortical neuron-enriched and mixed cortical neuron/glia co-cultures subjected to 
excitotoxic or hypoxic/ischemic insult. Together with investigating the effects of 
conditioned medium from PACAP-treated astrocytes on the survival of challenged 
cortical neurons in culture, these experiments will give important insight into whether 
PACAP directly inhibits neuronal apoptosis, supports neuronal survival via astroglial 
production of a neurotrophic factor, or modulates glial cells to reduce acute glutamate 
overload and minimize chronic inflammatory processes. 
It will also be of particular importance to further elucidate the biological 
significance of the PACAP target gene STC1 and to answer the question whether 
STC1 and non-canonical cAMP dependent signaling are implicated in PACAP‟s 
neuroprotective effects during ischemia. In cell culture, STC1 gene silencing with 
small interfering RNA (siRNA) could be employed to test whether STC1 is an 
essential mediator of PACAP‟s neuroprotective action. In vivo, the use of STC1-
deficient mice will give new insight into whether STC1 is involved in mediating 
PACAP‟s neuroprotective effects during ischemia (MCAO). Moreover, further 
studies are required to show whether STC1 has a direct neuroprotective effect or 
regulates neuroprotection indirectly, as also proposed for PACAP. STC1 might be 
released from neurons to regulate intermediary cells such as microglia to reduce 
inflammatory processes associated with tissue damage. 
PAC1 receptor coupling to second messenger production depends on the 
respective splice variant expressed. It will be interesting to investigate whether PAC1 
splice variants are dynamically regulated during prolonged stress and ischemic injury 
to provide differential second messenger production and target gene induction. 
Differential PACAP signaling might be an important regulatory mechanism 
implicated in the pleiotropic actions of PACAP during brain injury and stress-
responding in general. The engagement of non-canonical cAMP dependent signaling, 
in addition to the canonical pathway, which seems to be differentially regulated 
depending on cell type and maturation state, implies even more diversity in PACAP-
mediated signaling. A more complete understanding of the complex signaling 
pathways induced by PACAP for the induction of target genes in a variety of cell 
types will be crucial for the development of therapeutic strategies for the treatment of 
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stroke and other neurodegenerative and stress-associated diseases, based on PACAP‟s 
pharmacological and physiological effects in vivo. 
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